var title_f8_27_8624="Two nuclei diagnostic Reed-Sternberg cell";
var content_f8_27_8624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic Reed-Sternberg cell with two nuclei",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 190px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A diagnostic Reed-Sternberg cell with two nuclei is seen in the center (yellow arrow)&nbsp;with a prominent eosinophilic nucleolus present in each nucleus. There is some chromatin clearing around each nucleolus. Several mononuclear Reed-Sternberg variants are also present in the upper half of the field (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al, Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8624=[""].join("\n");
var outline_f8_27_8624=null;
var title_f8_27_8625="Isepamicin: International drug information";
var content_f8_27_8625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isepamicin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Exacin (JP);",
"     </li>",
"     <li>",
"      Isepacin (AT, IT, JP, MX, PT);",
"     </li>",
"     <li>",
"      Isepacine (BE);",
"     </li>",
"     <li>",
"      Isepalline (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Isepacine Sulfate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.M., I.V.: 8-15 mg/kg daily in 2 divided doses; maximum: 1.5 g/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: 250 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10398 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8625=[""].join("\n");
var outline_f8_27_8625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303775\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979102\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979104\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979107\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979103\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821241\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979106\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8626="Nevus central globular pattern";
var content_f8_27_8626=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of a nevus with a peripheral reticular and central globular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8626=[""].join("\n");
var outline_f8_27_8626=null;
var title_f8_27_8627="Hypoechoic hypervascular nodule Doppler";
var content_f8_27_8627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Hypoechoic hypervascular nodule Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A longitudinal image with Doppler interrogation of the left thyroid lobe that shows a hypoechoic, hypervascular nodule in its lower pole (N). Blood vessels are seen in the rest of the lobe (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bonavita, MD, Department of Radiology, NYU Langone Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8627=[""].join("\n");
var outline_f8_27_8627=null;
var title_f8_27_8628="Middle thyroid vein";
var content_f8_27_8628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Middle thyroid vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The middle thyroid vein is divided between clamps and tied with fine (3-0) silk sutures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8628=[""].join("\n");
var outline_f8_27_8628=null;
var title_f8_27_8629="Ticagrelor: Patient drug information";
var content_f8_27_8629=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ticagrelor: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     see \"Ticagrelor: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13159403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brilinta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12911320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brilinta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12925613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad bleeding. Follow how to use exactly. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3503724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than 100 mg a day of aspirin when taking this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12926065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3471937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ticagrelor or any other part of this drug",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3471970",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, bleeding problems, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3471975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not taking low dose aspirin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12990519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12926068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12926067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12926069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12990522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16785 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8629=[""].join("\n");
var outline_f8_27_8629=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911320\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925613\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926065\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990523\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990519\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926068\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990521\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926067\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990524\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12926069\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990522\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=related_link\">",
"      Ticagrelor: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8630="Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information";
var content_f8_27_8630=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=see_link\">",
"    see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/3/26676?source=see_link\">",
"    see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bebulin&reg; VH;",
"     </li>",
"     <li>",
"      Profilnine&reg; SD",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=see_link\">",
"      see \"Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemophilia B:",
"     </b>",
"     Children, Adolescents, and Adults: I.V.: Dosage is expressed in international units of factor IX activity and must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient (WHF, 2005). When multiple doses are required, administer at 24-hour intervals unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Formula for international units required to raise blood level %:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bebulin&reg; VH: In general, 1 international unit/kg of factor IX will increase the plasma factor IX level by 0.8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Number of Factor IX international units required = body weight (kg) x desired factor IX increase (as % of normal ) x 1.2 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX international units needed = 70 kg x 25 x 1.2 international unit/kg = 2100 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Profilnine&reg; SD: In general, 1 international unit/kg of factor IX will increase the plasma factor IX level by 1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Number of factor IX international units required = bodyweight (kg) x desired factor IX increase (as % of normal) x 1 international unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     For example, to increase factor IX level to 25% of normal in a 70 kg patient: Number of factor IX international units needed = 70 kg x 25 x 1 international unit/kg = 1750 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      As a general rule, the level of factor IX required for treatment of different conditions is listed below:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Minor bleeding (early hemarthrosis, minor epistaxis, gingival bleeding, mild hematuria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to 20% of normal [typical initial dose: 25-35 international units/kg]; generally a single dose is sufficient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Mild to moderate bleeding: Raise factor IX level to 20% to 30% of normal; generally a single dose is sufficient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Moderate bleeding (severe joint bleeding, early hematoma, major open bleeding, minor trauma, minor hemoptysis, hematemesis, melena, major hematuria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% of normal [typical initial dose: 40-55 international units/kg]; average duration of treatment is 2 days or until adequate wound healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Mild to moderate bleeding: Raise factor IX level to 20% to 30% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Major bleeding (severe hematoma, major trauma, severe hemoptysis, hematemesis, melena):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to &ge;60% of normal [typical initial dose: 60-70 international units/kg]; average duration of treatment is 2-3 days or until adequate wound healing. Do not raise &gt;60% in patients who may be predisposed to thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Raise factor IX level to 30% to 50% of normal; daily infusions are usually required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Surgical procedures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dental surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical dose: 50-60 international units/kg]. One infusion, administered 1 hour prior to surgery, is generally sufficient for the extraction of one tooth; for the extraction of multiple teeth, replacement therapy may be required for up to 1 week (see dosing guidelines for Minor Surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Raise factor IX level to 50% of normal immediately prior to procedure; administer additional doses if bleeding recurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Minor surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to 40% to 60% of normal on day of surgery [typical initial dose: 50-60 international units/kg]. Decrease factor IX level from 40% of normal to 20% of normal during initial postoperative period (1-2 weeks or until adequate wound healing) [typical dose: 55 international units/kg decreasing to 25 international units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Raise factor IX level to 30% to 50% of normal for at least 1 week following surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Major surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bebulin&reg; VH: Raise factor IX level to &ge;60% of normal on day of surgery [typical initial dose: 70-95 international units/kg]; do not raise &gt;60% in patients who may be predisposed to thrombosis. Decrease factor IX level from 60% of normal to 20% of normal during initial postoperative period (1-2 weeks) [typical dose: 70 international units/kg decreasing to 35 international units/kg]; further decrease to maintain a factor IX level of 20% of normal during late postoperative period (&ge;3 weeks) and continuing until adequate wound healing is achieved [typical dose: 35 international units/kg decreasing to 25 international units/kg]. The preoperative dose should be given 1 hour prior to surgery. The average dosing interval may be every 12 hours initially, then every 24 hours later in the postoperative period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Profilnine&reg; SD: Raise factor IX level to 30% to 50% of normal for at least 1 week following surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis, hemorrhage (long-term management):",
"     </b>",
"     Bebulin&reg; VH: 20-30 international units/kg/dose once or twice a week may reduce frequency of spontaneous hemorrhage; dosing regimen should be individualized.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bebulin&reg; VH: Exact potency labeled on each vial [vapor heated; contains heparin and natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Profilnine&reg; SD: ~500 units, ~1000 units, ~1500 units [exact potency labeled on each vial; solvent/detergent treated]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. administration only; infuse slowly; rate of administration should be individualized for patient's comfort; rapid I.V. administration may cause vasomotor reactions; maximum rates of administration: Bebulin&reg; VH: 2 mL/minute; Profilnine&reg; SD: 10 mL/minute; visually inspect for particulate matter and discoloration prior to administration whenever permitted by solution or container.",
"     <b>",
"      Note:",
"     </b>",
"     Slowing the rate of infusion, changing the lot of medication, or administering antihistamines may relieve some adverse reactions",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Profilnine&reg; SD: May store unopened vials at room temperature (&lt;30&deg;C) for up to 3 months. Administer within 3 hours after reconstitution;",
"     <b>",
"      do not refrigerate after reconstitution",
"     </b>",
"     ; discard unused portion.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and control of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease) (Profilnine&reg; SD: FDA approved in ages &gt;16 years and adults; Bebulin&reg; VH: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14634078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor IX Complex may be confused with Factor IX",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, thrombosis (sometimes fatal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, lethargy, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock, clotting factor antibodies (development of), heparin-induced thrombocytopenia (with products containing heparin)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to factor IX complex or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe closely for signs or symptoms of intravascular coagulation or thrombosis. Use with caution when administering to patients with liver disease, postoperatively,  or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation, or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. Products do not contain therapeutic levels of factor VII and should not be used for the treatment of factor VII deficiency. Some products (eg, Bebulin&reg; VH) contain natural rubber latex (in certain components of the product packaging) which may cause allergic reactions in susceptible individuals; avoid use in patients with allergy to latex. Some products contain heparin; use with caution in patients with a history of heparin-induced thrombocytopenia.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7812025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Human factor IX complex is prepared from human plasma and even with heat treated or other viral attenuated processes, the risk of viral transmission (ie, viral hepatitis, HIV, parvovirus B19, and theoretically, Creutzfeldt-Jacob disease agent) is not totally eradicated. Hepatitis B vaccination and hepatitis A vaccination are recommended for patients with hemophilia (at birth or at diagnosis). Serious and potentially fatal thrombosis or DIC may occur in patients with hepatic impairment and in patients undergoing surgery (risk is greater following surgery); use with caution in these patients; consider risk versus benefit before prescribing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential allergic reactions, the initial ~10-20 administrations should be performed under appropriate medical supervision. Patients experiencing allergic reactions should be evaluated for factor IX inhibitors. The development of factor IX inhibitors (or antibodies) usually occurs within the first 10-20 exposure days to factor IX therapy; the presence of inhibitors increases the risk of severe hypersensitivity reactions. Patients with severe gene defects (eg, gene deletion or inversion) are more likely to develop inhibitors. When clinical response is suboptimal or patient is to undergo surgical procedure, screening for inhibitors should be completed (WFH, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminocaproic Acid: May enhance the adverse/toxic effect of Factor IX Complex (Human). Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7281044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levels of factors II, IX, and X; signs/symptoms of hypersensitivity reactions and bleeding; hemoglobin, hematocrit; screen for factor IX inhibitors by measuring inhibitor titers (children: Every 3-12 months or 10-20 exposure days)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with severe hemophilia will have factor IX levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. Plasma concentration is about 4 mg/L.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient clotting factors including factor IX (antihemophilic factor B); also contains factor II (prothrombin), factor X, and low amounts of factor VII. Hemophilia B, or Christmas disease, is an X-linked recessively inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Half-life: Cleared rapidly from the serum in two phases:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     First phase: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Terminal: 22.5 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lee JW, \"Von Willebrand Disease, Hemophilia A and B, and Other Factor Deficiencies,\"",
"      <i>",
"       Int Anesthesiol Clin",
"      </i>",
"      , 2004, 42(3):59-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/27/8630/abstract-text/15205640/pubmed\" id=\"15205640\" target=\"_blank\">",
"        15205640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lusher JM, &ldquo;Thrombogenicity Associated With Factor IX Complex Concentrates,&rdquo;",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 1991, 28(3 Suppl 6):3-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/27/8630/abstract-text/1780767/pubmed\" id=\"1780767\" target=\"_blank\">",
"        1780767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;Guidelines for Emergency Department Management of Individuals With Hemophilia,&rdquo; 2006. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/175.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders,&rdquo; 2010. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac190.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding),&rdquo; 2007. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shord SS and Lindley CM, &ldquo;Coagulation Products and Their Uses,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(15):1403-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/27/8630/abstract-text/ 10938981 /pubmed\" id=\" 10938981 \" target=\"_blank\">",
"        10938981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Federation of Hemophilia, &ldquo;Guidelines for the Management of Hemophilia,&rdquo; 2005. Available at file://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13293 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8630=[""].join("\n");
var outline_f8_27_8630=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169679\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052661\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052655\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169668\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169654\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052665\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052658\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052664\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634078\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169695\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052668\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052654\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7812025\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299308\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169663\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7281044\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052660\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052663\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052667\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/30/18919?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/3/26676?source=related_link\">",
"      Unactivated prothrombin complex concentrates (3 factors: IX, II, X [and trace VII]): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8631="Fungal peritonitis in continuous peritoneal dialysis";
var content_f8_27_8631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fungal peritonitis in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8631/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/27/8631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing maintenance dialysis have a markedly increased incidence of fungal infection. A retrospective review of more than 300,000 patients in the United States Renal Data System from 1992 to 1997 demonstrated that dialysis patients had an age-adjusted incidence ratio for fungal infections of 9.8 compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/1\">",
"     1",
"    </a>",
"    ]. The vast majority of these fungal infections were due to Candida species (79 percent).",
"   </p>",
"   <p>",
"    The majority of fungal infections in patients with end-stage renal disease are related to the technique of peritoneal dialysis (PD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients undergoing PD, peritonitis resulting from fungi carries a higher morbidity and mortality than bacterial infections. Reported complications include sclerosing peritonitis, adhesions with resulting bowel obstructions or stricture, invasion of the bowel wall, and abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/3\">",
"     3",
"    </a>",
"    ]. Extraperitoneal spread of infection is unusual and mortality is usually related to underlying conditions.",
"   </p>",
"   <p>",
"    An overview of fungal peritonitis in patients undergoing continuous peritoneal dialysis is presented in this topic review. A general overview of peritonitis in PD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the peritoneal space are the main complication of PD; they are usually caused by staphylococcal species. By comparison, fungi are responsible for 2 to 13 percent of such cases. Most fungal PD-associated infections are due to Candida species, especially C. albicans and C parapsilosis. Assorted molds and yeasts, such as species of Aspergillus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/4\">",
"     4",
"    </a>",
"    ], Fusarium, Rhodotorula, Zygomycetes and dematiaceous molds, are occasionally observed. Fungi, when found with bacteria as part of a polymicrobial peritonitis, are a predictor of a poor response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons for contamination of peritoneal fluid with fungi are breaks in sterile technique when connecting peritoneal catheters to bags of dialysate, infections at the cutaneous site of catheter entry, intestinal perforation, peritoneovaginal fistulae, and transmigration of fungi across the bowel wall into the peritoneum.",
"   </p>",
"   <p>",
"    The presence of certain additional factors in PD patients increases the risk for fungal peritonitis. Almost all published series have found an association with both recent antibacterial use and episodes of bacterial peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/2,6-11\">",
"     2,6-11",
"    </a>",
"    ]. When these series are combined, 65 percent of patients had been exposed to antibiotics within 30 days of the onset of fungal peritonitis and 48 percent had experienced an episode of bacterial peritonitis within the same time frame.",
"   </p>",
"   <p>",
"    It is difficult to determine whether antibiotic exposure and peritoneal inflammation actually predispose to fungal infections or whether these factors merely identify a high-risk group of patients prone to peritonitis because of poor technique. Recent exposure to antibiotics may predispose to fungal peritonitis by shifting the balance of the patients' endogenous skin and bowel flora towards yeast species, thereby increasing the chances of contamination during catheter manipulation.",
"   </p>",
"   <p>",
"    Other risk factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of emergency peritoneal dialysis &mdash; A trend towards infection with fungal organisms has been observed in association with acute or emergent PD performed in the hospital; this may be due to the severity of illness of these patients, concurrent treatment with antibacterial agents, or the administration of dialysis by personnel unfamiliar with the techniques associated with PD.",
"     </li>",
"     <li>",
"      HIV infection &mdash; Patients with HIV infection who receive chronic PD have a higher frequency of peritonitis with yeasts when compared to other chronic PD patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=see_link\">",
"       \"Human immunodeficiency virus and dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extraperitoneal fungal infection",
"     </li>",
"     <li>",
"      Abdominal surgery",
"     </li>",
"     <li>",
"      Environmental exposures &mdash; There are reports of outbreaks of Candida peritonitis associated with contamination of water baths used to warm dialysate solutions and even environmental contact with pigeon guano [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In addition, contact with soil during gardening or recreation may lead to peritonitis with certain molds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of fungal peritonitis in PD patients are the same as those for bacterial peritonitis. The most consistent findings are a cloudy dialysate and abdominal pain that occur in approximately 90 and 75 percent of patients, respectively. Abdominal pain, that is usually diffuse, may be associated with nausea, vomiting, and diarrhea. The symptoms may also be subtle, consisting of only mild abdominal pain and low-grade fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients have an elevated temperature; examination of the abdomen typically displays signs of peritonitis, including diffuse tenderness with guarding, rebound tenderness, abdominal distention, and decreased bowel sounds. Poor return of the dialysate during episodes of fungal peritonitis occurs more frequently with infections by molds, which can potentially block catheter ports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When examining the dialysate fluid for fungal infection, attention should be paid to the duration of the dwell and whether or not peritoneal lavage was performed prior to sample collection; these factors can influence cell counts and culture. As for all PD-associated peritonitis, the criterion for infection is a cell count &gt;100 cells &micro;L with &gt;50 percent polymorphonuclear cells. However, among patients with fungal peritonitis, the peritoneal white blood count is almost always greater than 200",
"    <span class=\"nowrap\">",
"     cells/&micro;L,",
"    </span>",
"    with a polymorphonuclear cell predominance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\", section on 'Peritoneal fluid cell count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although local eosinophilia is a frequent transient finding during the first few weeks after initiating PD, peritoneal eosinophilia has also been described with certain mold infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/14\">",
"     14",
"    </a>",
"    ]. The finding of eosinophils in the peritoneal fluid of a patient on chronic PD with suspected infection should raise the consideration of fungi as etiologic agents.",
"   </p>",
"   <p>",
"    Gram stain of the peritoneal fluid may reveal yeasts consistent with Candida. However, other stains, such as calcofluor white, are more sensitive for other fungi.",
"   </p>",
"   <p>",
"    The diagnosis of fungal peritonitis is made by culturing the dialysate fluid. It is recommended that at least ten milliliters of peritoneal fluid be sent for fungal culture. Although Candida species usually grow quickly in culture, other fungi may require weeks to emerge. The diagnosis therefore requires a high level of suspicion, with some cases presenting as culture-negative peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general goals of treatment should be twofold: the infection should be eradicated and the peritoneum should be preserved for future use in PD. Upon diagnosis of fungal peritonitis, the peritoneum should therefore be lavaged until the returning fluid is clear; this helps prevent adhesions and lowers the fungal burden. Prompt initiation of antifungal therapy is indicated if a calcofluor white or Gram stain reveals yeast or hyphae. Subsequent therapy is based upon culture results, susceptibility of the organism, and patient response.",
"   </p>",
"   <p>",
"    As stated in multiple guidelines, it is recommended that the catheter be removed immediately after fungi are identified by microscopy or culture and that the patient should be placed on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The IDSA guidelines for treatment of candidiasis, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's website [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a very small subset of patients, with yeast peritonitis occurring within two weeks of initiation of PD for acute renal failure, in whom antifungal therapy alone may result in cure. If an infection with a mold arises in this same group of patients, however, catheter removal is almost always required to achieve a cure.",
"   </p>",
"   <p>",
"    Instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    into the peritoneal cavity has occasionally been used as the sole or adjunctive therapy. However, this regimen is also discouraged because:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is not consistently successful in curing infections.",
"     </li>",
"     <li>",
"      It is a frequent cause of abdominal pain upon instillation.",
"     </li>",
"     <li>",
"      It can contribute to adhesion formation with subsequent loss of the peritoneum as a dialyzing membrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decisions regarding the type of antifungal chemotherapy should be based upon the patient's clinical state and on the particular fungus causing infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommended strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We propose the following strategy for fungal peritonitis associated with PD. If the dialysate is grossly turbid, peritoneal lavage should be continued until the returning fluid is clear. Systemic antifungals should be given, and the catheter should be removed as soon as possible. Prompt initiation of antifungal therapy is indicated if a calcofluor white or Gram stain reveals yeast or hyphae.",
"   </p>",
"   <p>",
"    The choice of antifungal agent varies based upon the specific infecting organism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For empiric coverage of fungal peritonitis when there is no suggestion of the identity of the fungus from inspection of the fluid and until cultures return, we recommend oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      For patients who have had significant prior exposure to azole antifungals, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or an intravenous echinocandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      [70 mg on day one, with subsequent dosing of 50",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      [100",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      [200 mg on day one, with subsequent dosing of 100",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]. After cultures return, further therapy can be tailored to the specific organism that has been isolated.",
"     </li>",
"     <li>",
"      If Candida species are found, susceptibility studies can be requested for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      to help direct therapy. Generally, C. albicans, C. parapsilosis, and C. tropicalis are susceptible to fluconazole, C. krusei is resistant, and C. glabrata has variable susceptibilities, but generally is resistant.",
"     </li>",
"     <li>",
"      If the fluid cultures yield C. albicans, C. tropicalis, or C. parapsilosis, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      at 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/16,25,26\">",
"       16,25,26",
"      </a>",
"      ]. The duration of therapy is generally two to four weeks.",
"     </li>",
"     <li>",
"      If the fluid cultures yield C. krusei or C. glabrata, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      at a dose of 0.6 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or an intravenous echinocandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      [70 mg on day one, with subsequent dosing of 50",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      [100",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      [200 mg on day one, with subsequent dosing of 100",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]. Patients should be treated for four weeks.",
"     </li>",
"     <li>",
"      If the fluid cultures yield a mold, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      at 0.6 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day until the specific organism is identified and the most appropriate antifungal agent can be given. For Aspergillus species,",
"      <strong>",
"       oral",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is a reasonable alternative to amphotericin B [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients should be treated for at least four weeks and until all symptoms and signs have resolved.",
"     </li>",
"     <li>",
"      Infections due to dematiaceous molds should be treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (loading dose of 200 mg three times daily for three days followed by 200 mg twice a day) or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (loading dose of 400 mg twice daily for the first day followed by 200 mg twice a day), although some cases have responded to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Patients should be treated for at least four weeks and until all symptoms and signs have resolved.",
"     </li>",
"     <li>",
"      There is limited experience using lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/30,31\">",
"       30,31",
"      </a>",
"      ], but they should be as effective as the deoxycholate formulation. Because nephrotoxicity is not an issue in these patients, these agents likely will only be used in patients who experience severe infusion-related reactions to the deoxycholate formulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The experience with echinocandins in CAPD-associated fungal peritonitis is only anecdotal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/20\">",
"     20",
"    </a>",
"    ]. However, all three echinocandins have proven effective for the treatment of candidemia. In all of the randomized controlled trials of echinocandins for candidiasis, a small number of patients had peritoneal infection and responded well to the echinocandin agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient should be maintained with hemodialysis during treatment with systemic antifungal agents. After peritoneal dialysis catheter removal, common practice involves waiting for at least a four to six week period prior to placement of a new PD catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with other causes of peritonitis, fungal peritonitis in PD is associated with decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/32\">",
"     32",
"    </a>",
"    ]. Reported mortality rates have ranged from 15 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/16,32,33\">",
"     16,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data suggest that antifungal prophylaxis during the course of antibiotic therapy may reduce the incidence of fungal peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8631/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. We generally give antifungal prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    (400,000 to 500,000 orally three times daily) to PD patients who receive prolonged antibiotics (defined as antibiotic duration beyond a single dose). Prophylactic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is not recommended because of a major concern regarding selection for fluconazole-resistant organisms that are more difficult to treat. Routine prophylaxis for all PD patients (ie, in the absence of prolonged antibiotic therapy) is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30746741\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing maintenance peritoneal dialysis (PD) have a markedly increased incidence of fungal infection compared to the general population. Fungi are responsible for 2 to 13 percent of all cases of PD-associated peritonitis. Most fungal infections are due to Candida species. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reasons for fungal peritonitis include breaks in sterile technique, infections at the cutaneous site of catheter entry, intestinal perforation, peritoneovaginal fistulae, and transmigration of fungi across the bowel wall into the peritoneum. Other risk factors include recent antibacterial use, episodes of bacterial peritonitis, emergent PD, HIV infection; extraperitoneal fungal infection, abdominal surgery, and environmental exposures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Causes and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and signs of fungal peritonitis in PD patients are the same as those for bacterial peritonitis. The most consistent findings are a cloudy dialysate and diffuse abdominal pain. Abdominal pain may be associated with nausea, vomiting, and diarrhea. The symptoms may also be subtle, consisting of only mild abdominal pain and low-grade fever. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and signs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"       \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The criterion for diagnosis of PD-associated peritonitis is a peritoneal cell count &gt;100 cells &micro;L with &gt;50 percent polymorphonuclear cells; the cell count is usually &gt;200",
"      <span class=\"nowrap\">",
"       cells/&micro;L",
"      </span>",
"      among patients with fungal peritonitis. Gram stain of the peritoneal fluid may reveal yeasts consistent with Candida. The diagnosis is made by culturing the dialysate fluid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory findings and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment include both eradication of infection and preservation of the peritoneum for future use for dialysis. If the dialysate is grossly turbid, peritoneal lavage should be done until the returning fluid is clear. Systemic antifungals should be given, and the catheter should be removed as soon as possible. Prompt initiation of antifungal therapy is indicated if a calcofluor white or Gram stain reveals yeast or hyphae. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommended strategy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The choice of antifungal agent varies based upon the specific infecting organism:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be used for empiric coverage of fungal peritonitis when there is no suggestion of the identity of the fungus from inspection of the fluid and until cultures return.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or an intravenous echinocandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      [70 mg on day one, with subsequent dosing of 50",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      [100",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      [200 mg on day one, with subsequent dosing of 100",
"      <span class=\"nowrap\">",
"       mg/day])",
"      </span>",
"      may be used for empiric coverage for patients who have had significant prior exposure to azole antifungals,",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After cultures return, further therapy can be tailored to the specific organism that has been isolated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommended strategy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If Candida species are found, susceptibility studies can be requested for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      to help direct therapy.",
"     </li>",
"     <li>",
"      For C. albicans, C. tropicalis, or C. parapsilosis, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      at 200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The duration of therapy is generally two to four weeks.",
"     </li>",
"     <li>",
"      For C. krusei or C. glabrata, we use intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      at a dose of 0.6 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or an intravenous echinocandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      [70 mg on day one, with subsequent dosing of 50",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      [100",
"      <span class=\"nowrap\">",
"       mg/day],",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      [200 mg on day one, with subsequent dosing of 100",
"      <span class=\"nowrap\">",
"       mg/day]).",
"      </span>",
"      Patients should be treated for four weeks.",
"     </li>",
"     <li>",
"      For a mold, we use intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      at 0.6 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day until the specific organism is identified and the most appropriate antifungal agent can be given.",
"     </li>",
"     <li>",
"      For Aspergillus species,",
"      <strong>",
"       oral",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is a reasonable alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      . Patients should be treated for at least four weeks and until all symptoms and signs have resolved.",
"     </li>",
"     <li>",
"      Infections due to dematiaceous molds should be treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (loading dose of 200 mg three times daily for three days followed by 200 mg twice a day) or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (loading dose of 400 mg twice daily for the first day followed by 200 mg twice a day). Patients should be treated for at least four weeks and until all symptoms and signs have resolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be maintained with hemodialysis during treatment with systemic antifungal agents. After PD catheter removal, common practice involves waiting for at least a four to six week period prior to placement of a new PD catheter. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommended strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observational data suggest that antifungal prophylaxis during the course of antibiotic therapy may reduce the incidence of fungal peritonitis. For PD patients who receive prolonged antibiotics (defined as antibiotic duration beyond a single dose), we suggest the administration of antifungal prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      (400,000 to 500,000 orally three times daily). We recommend not giving prophylactic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      because of a major concern regarding selection for fluconazole-resistant organisms that are more difficult to treat. We recommend not providing routine prophylaxis for all PD patients (ie, in the absence of prolonged antibiotic therapy). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/1\">",
"      Abbott KC, Hypolite I, Tveit DJ, et al. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron 2001; 89:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/2\">",
"      Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2005; 25:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/3\">",
"      Uchida M, Sakemi T, Nagano Y, Mizuguchi M. Rectal stenosis associated with fungal peritonitis: a complication of continuous ambulatory peritoneal dialysis. Nephron 1989; 53:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/4\">",
"      Schwetz I, Horina J, Buzina W, et al. Aspergillus oryzae peritonitis in CAPD: case report and review of the literature. Am J Kidney Dis 2007; 49:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/5\">",
"      Szeto CC, Chow KM, Wong TY, et al. Conservative management of polymicrobial peritonitis complicating peritoneal dialysis--a series of 140 consecutive cases. Am J Med 2002; 113:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/6\">",
"      Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/7\">",
"      Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 1986; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/8\">",
"      Nagappan R, Collins JF, Lee WT. Fungal peritonitis in continuous ambulatory peritoneal dialysis--the Auckland experience. Am J Kidney Dis 1992; 20:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/9\">",
"      Rubin J, Kirchner K, Walsh D, et al. Fungal peritonitis during continuous ambulatory peritoneal dialysis: a report of 17 cases. Am J Kidney Dis 1987; 10:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/10\">",
"      Tapson JS, Mansy H, Freeman R, Wilkinson R. The high morbidity of CAPD fungal peritonitis--description of 10 cases and review of treatment strategies. Q J Med 1986; 61:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/11\">",
"      Bren A. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1998; 17:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/12\">",
"      Greaves I, Kane K, Richards NT, et al. Pigeons and peritonitis? Nephrol Dial Transplant 1992; 7:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/13\">",
"      Yuen KY, Seto WH, Ching TY, et al. An outbreak of Candida tropicalis peritonitis in patients on intermittent peritoneal dialysis. J Hosp Infect 1992; 22:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/14\">",
"      Nankivell BJ, Pacey D, Gordon DL. Peritoneal eosinophilia associated with Paecilomyces variotii infection in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/15\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/16\">",
"      Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/17\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/18\">",
"      Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/20\">",
"      Madariaga MG, Tenorio A, Proia L. Trichosporon inkin peritonitis treated with caspofungin. J Clin Microbiol 2003; 41:5827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/21\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/22\">",
"      Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/23\">",
"      Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/24\">",
"      Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/25\">",
"      Chan TM, Chan CY, Cheng SW, et al. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. Nephrol Dial Transplant 1994; 9:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/26\">",
"      Vas S, Oreopoulos DG. Infections in patients undergoing peritoneal dialysis. Infect Dis Clin North Am 2001; 15:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/27\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/28\">",
"      Greig J, Harkness M, Taylor P, et al. Peritonitis due to the dermatiaceous mold Exophiala dermatitidis complicating continuous ambulatory peritoneal dialysis. Clin Microbiol Infect 2003; 9:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/29\">",
"      Lau SK, Woo PC, Chiu SK, et al. Early diagnosis of Exophiala CAPD peritonitis by 18S ribosomal RNA gene sequencing and its clinical significance. Diagn Microbiol Infect Dis 2003; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/30\">",
"      Serna JH, Wanger A, Dosekun AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. Am J Kidney Dis 2003; 42:E14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/31\">",
"      Nannini EC, Paphitou NI, Ostrosky-Zeichner L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003; 46:49.",
"     </a>",
"    </li>",
"    <li>",
"     Tzamaloukas, AH, Fox, L. Infections in Patients on Peritoneal Dialysis, Chapter 41, in Principles and Practice of Dialysis, Henrich, WL (Ed). Lippincott Williams and Wilkins, New York, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/33\">",
"      Amici G, Grandesso S, Mottola A, et al. Fungal peritonitis in peritoneal dialysis: critical review of six cases. Adv Perit Dial 1994; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/34\">",
"      Z&aacute;ruba K, Peters J, Jungbluth H. Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years' experience. Am J Kidney Dis 1991; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/35\">",
"      Moreiras-Plaza M, Vello-Rom&aacute;n A, Sampr&oacute;m-Rodr&iacute;guez M, Feij&oacute;o-Pi&ntilde;eiro D. Ten years without fungal peritonitis: a single center's experience. Perit Dial Int 2007; 27:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8631/abstract/36\">",
"      Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007; 27:531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1982 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8631=[""].join("\n");
var outline_f8_27_8631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30746741\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommended strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30746741\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=related_link\">",
"      Human immunodeficiency virus and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8632="Etiology and clinical manifestations of cervical lymphadenitis in children";
var content_f8_27_8632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and clinical manifestations of cervical lymphadenitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Douglas S Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8632/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/27/8632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lymphadenitis is common in childhood. The incidence is difficult to ascertain because it is usually caused by a viral upper respiratory illness (URI) and is self-limited.",
"   </p>",
"   <p>",
"    The etiology, pathophysiology, and clinical manifestations of cervical lymphadenitis in children will be reviewed here. The evaluation and treatment of cervical lymphadenitis in children is discussed separately, as is peripheral lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link\">",
"     \"Causes of peripheral lymphadenopathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lymphadenitis is defined as enlarged, inflamed, and tender lymph node(s) of the neck. Cervical lymphadenopathy refers simply to enlarged lymph node(s) of the neck. However, the two terms often are used interchangeably. Acute lymphadenitis develops over a few days, whereas",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    lymphadenitis develops over weeks to months.",
"   </p>",
"   <p>",
"    Generalized lymphadenopathy is the enlargement of two or more noncontiguous lymph node regions (ie, cervical and axillary) and is the result of systemic disease. Generalized lymphadenopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Generalized lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Generalized nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph nodes frequently associated with cervicofacial lymphadenitis of childhood and the anatomic areas they drain are listed in the Table (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"UTD.htm?18/53/19285\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77551 \" href=\"UTD.htm?30/62/31723\">",
"     table 1",
"    </a>",
"    ). More than 80 percent of childhood cervical lymphadenitis involves the submandibular or deep cervical nodes because they filter much of the lymphatic fluid from the head and neck. The jugulodigastric (tonsillar) node, part of the superior deep cervical nodes and located below the mandible at the angle of the jaw, is commonly involved in cervical adenitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of cervical lymphadenitis has not been fully elucidated, but it is suspected that microorganisms penetrate the mucosa or skin of the head and neck, infiltrate the surrounding tissue, and are transported by afferent lymph vessels to lymph nodes. Although obvious infection of the anatomically drained area may be present, the infiltration of organisms often is asymptomatic, with no clinical evidence of an inoculation site. If the lymph nodes filter infectious and antigenic materials from the lymphatic fluid, lymphocytes proliferate, causing subsequent nodal enlargement.",
"   </p>",
"   <p>",
"    Involvement of pyogenic organisms, such as",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    and",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    (group A streptococcus [GAS]), usually results in acute reactions within the lymph node, manifested by a sudden onset of swelling, erythema, warmth, and tenderness. Recruitment of neutrophils to the lymph node may result in abscess formation. Mycobacterial, fungal, and",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    infections generate a more chronic granulomatous inflammatory response with typically less dramatic clinical features, although suppuration can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous infectious and noninfectious causes of cervical lymphadenitis (",
"    <a class=\"graphic graphic_table graphicRef56712 \" href=\"UTD.htm?6/55/7037\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77911 \" href=\"UTD.htm?11/21/11612\">",
"     table 3",
"    </a>",
"    ). Cervical lymphadenitis in children is usually caused by an infectious process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious causes of cervical lymphadenitis frequently are considered in four broad categories (",
"    <a class=\"graphic graphic_table graphicRef56712 \" href=\"UTD.htm?6/55/7037\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute bilateral cervical lymphadenitis",
"     </li>",
"     <li>",
"      Acute unilateral cervical lymphadenitis",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Subacute/chronic",
"      </span>",
"      bilateral lymphadenitis",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Subacute/chronic",
"      </span>",
"      unilateral lymphadenitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of the most common infectious causes of cervical lymphadenitis in children are described below. The diagnostic approach to children with cervical lymphadenitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Noninfectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious causes of cervical lymphadenopathy in children are less common but always should be considered in the differential diagnosis. Important noninfectious causes of cervical lymphadenitis in children include (",
"    <a class=\"graphic graphic_table graphicRef77911 \" href=\"UTD.htm?11/21/11612\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Connective tissue disorders",
"     </li>",
"     <li>",
"      Leukemia",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Kawasaki disease",
"     </li>",
"     <li>",
"      Periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA)",
"     </li>",
"     <li>",
"      Kikuchi disease",
"     </li>",
"     <li>",
"      Medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of the most common noninfectious causes of cervical lymphadenitis in children are described below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Noninfectious causes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACUTE BILATERAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bilateral cervical lymphadenitis is the most common clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Viral URI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bilateral cervical lymphadenitis is most often caused by a benign, self-limited viral upper respiratory infection (eg, enterovirus, adenovirus, influenza virus). Patients often have a history of an ill contact and current or recent symptoms that may include sore throat, rhinorrhea, nasal congestion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=see_link&amp;anchor=H6#H6\">",
"     \"The common cold in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lymph nodes typically are small, rubbery, mobile, discrete, minimally tender, and without erythema or warmth; they are often referred to as \"reactive\" or \"shotty\" lymphadenopathy. Although the clinical course is self-limited, the lymphadenopathy may last for weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Group A streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcal (GAS) pharyngitis is a common cause of bilateral cervical lymphadenitis, which is often tender. GAS pharyngitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bilateral cervical lymphadenitis also is associated with pharyngitis resulting from",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    and primary gingivostomatitis due to herpes simplex virus. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) usually cause generalized lymphadenopathy but may present as acute bilateral cervical lymphadenitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE UNILATERAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute unilateral cervical lymphadenitis occurs less frequently than acute bilateral cervical lymphadenitis. Acute unilateral cervical lymphadenitis is usually caused by bacteria (",
"    <em>",
"     S. aureus",
"    </em>",
"    , group A streptococcus [GAS], and, in young infants,",
"    <em>",
"     Streptococcus agalactiae",
"    </em>",
"    [group B streptococcus, or GBS]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     S. aureus and GAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 40 and 80 percent of cases of acute unilateral cervical lymphadenitis are caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef74121 \" href=\"UTD.htm?18/6/18542\">",
"     picture 1",
"    </a>",
"    ) or GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Clinical features are usually not helpful in differentiating between staphylococcal and streptococcal adenitis. Most of these infections occur in children younger than five years of age. Patients may have a history of a recent URI or impetigo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although systemic symptoms of fever, tachycardia, and malaise may be present, the patient usually does not appear toxic. Submandibular nodes are affected in more than 50 percent of cases. The lymph node usually is 3 to 6 cm in diameter, tender, warm, erythematous, nondiscrete, and poorly mobile. One-fourth to one-third of infected nodes suppurate and become fluctuant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Group B streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS cellulitis-adenitis usually is a manifestation of late-onset GBS infection (which has onset between 7 and 89 days of age). Affected infants usually are between three and seven weeks of age, male, febrile, and irritable, and have poor feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Examination reveals tender, erythematous facial or submandibular swelling with ill-defined margins. Bacteremia is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H19#H19\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Other focal infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anaerobic bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute unilateral cervical lymphadenitis in older children with history of periodontal disease usually is caused by an infection with anaerobic bacteria. In one study, anaerobic bacteria were isolated from 38 percent of lymph node aspirates, collected primarily from children with dental disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/7\">",
"     7",
"    </a>",
"    ]. Lymph node examination cannot distinguish anaerobic infection from lymphadenitis resulting from",
"    <em>",
"     S. aureus",
"    </em>",
"    or GAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tularemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is a febrile illness caused by an infection with",
"    <em>",
"     Francisella tularensis",
"    </em>",
"    that usually occurs following contact with infected animals (eg, rabbits, pet hamsters) or the bite of blood-sucking arthropods. The most common clinical presentation is the ulceroglandular syndrome, characterized by a papular lesion in the drainage field of the inflamed lymph node (",
"    <a class=\"graphic graphic_picture graphicRef52036 \" href=\"UTD.htm?5/19/5439\">",
"     picture 2",
"    </a>",
"    ). Most cases in the United States occur in the south-central region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUBACUTE/CHRONIC BILATERAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute/chronic",
"    bilateral lymphadenitis is most commonly seen Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infections. It also may be caused by tuberculosis, HIV, toxoplasmosis, and",
"    <span class=\"nowrap\">",
"     syphilis.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     EBV and CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute/chronic",
"    bilateral cervical lymphadenitis is most often caused by EBV or CMV infection. EBV causes infectious mononucleosis that may manifest as fever, exudative pharyngitis, lymphadenopathy, and hepatosplenomegaly. CMV also can cause a mononucleosis-like illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis is an uncommon cause of chronic cervical adenitis that is usually unilateral but occasionally can be bilateral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=see_link\">",
"     \"Tuberculous lymphadenitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other uncommon causes of chronic bilateral cervical adenitis include HIV infection, toxoplasmosis, and syphilis, all of which are usually associated with generalized lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Lymphadenopathy'",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840505#H18840505\">",
"      \"Natural history and classification of pediatric HIV infection\", section on 'Clinical manifestations'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUBACUTE/CHRONIC UNILATERAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute/chronic",
"    unilateral cervical lymphadenitis is usually caused by nontuberculous mycobacteria (NTM) infections or",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    , the agent of cat scratch disease (CSD). However, it also may be caused by tuberculosis or toxoplasmosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10472015\">",
"    <span class=\"h2\">",
"     NTM infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most NTM infections occur in immunocompetent children younger than five years of age. The organisms are ubiquitous and can be found in soil, dust, and water. The",
"    <em>",
"     Mycobacterium avium",
"    </em>",
"    complex (MAC) is responsible for the vast majority of NTM cervical adenitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link&amp;anchor=H2272512904#H2272512904\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM lymphadenitis generally presents as a unilateral firm, nontender node that slowly enlarges over several weeks. The submandibular or tonsillar nodes are most commonly infected and usually are less than 4 cm in size. The overlying skin gradually changes from a pink color to a violaceous hue and thins to a parchment-like appearance (",
"    <a class=\"graphic graphic_picture graphicRef69475 \" href=\"UTD.htm?40/60/41934\">",
"     picture 3",
"    </a>",
"    ). Fever, pain, and tenderness are unusual. Suppuration and formation of a draining sinus tract that can persist for months frequently occurs in untreated lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link&amp;anchor=H2272512912#H2272512912\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cat scratch disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSD is a relatively common infection caused by inoculation of",
"    <em>",
"     B. henselae",
"    </em>",
"    into the skin following a cat bite or scratch [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. From 7 to 60 days following the scratch, the lymph node draining the site of inoculation becomes warm, tender, and slightly erythematous (",
"    <a class=\"graphic graphic_picture graphicRef52407 \" href=\"UTD.htm?33/63/34814\">",
"     picture 4",
"    </a>",
"    ). There is usually (but not always) a history of contact with a cat, often a kitten, although patients and parents frequently do not recall a bite or scratch. Careful physical examination may reveal a papule at the primary site of inoculation (",
"    <a class=\"graphic graphic_picture graphicRef78770 \" href=\"UTD.htm?7/60/8128\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever and mild systemic symptoms occur in 30 percent of patients and can last for four to six weeks. Occasionally, infection may manifest as Parinaud oculoglandular syndrome, with conjunctivitis and ipsilateral preauricular or submandibular adenitis following conjunctival inoculation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link&amp;anchor=H12#H12\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\", section on 'Parinaud's oculoglandular syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric tuberculosis (TB) is relatively uncommon in the United States but remains a significant cause of cervical lymphadenitis in other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/11\">",
"     11",
"    </a>",
"    ]. Infection of the cervical nodes is usually caused by extension from the paratracheal nodes to the tonsillar and submandibular nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/12\">",
"     12",
"    </a>",
"    ]. It also can occur by direct spread from the apical pleura to the supraclavicular nodes. Clinical symptoms compatible with TB, an abnormal CXR, a history of contact with persons who have symptoms of TB, or a history of travel to an endemic area for TB should prompt an evaluation for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=see_link\">",
"     \"Tuberculous lymphadenitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    infection is symptomatic in only 10 percent of patients, in whom lymphadenopathy and fatigue without fever are the most common manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/14\">",
"     14",
"    </a>",
"    ]. The disease is usually benign and self-limited. Adenopathy is discrete, nonsuppurative, sometimes tender, and may persist for months. Oocysts are excreted from the stool of cats, the definitive host for",
"    <em>",
"     T. gondii",
"    </em>",
"    . Human infection occurs by ingesting poorly cooked meat that contains cysts or by inadvertently ingesting mature oocysts from soil, litter boxes, or contaminated food. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious causes of cervical lymphadenopathy in children are less common but always should be considered in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Connective tissue disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged fever, rash, and arthralgias suggest a possible connective tissue disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neoplasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemia or lymphoma should be suspected in patients with persistent or progressive nontender cervical or generalized lymphadenopathy; no evidence of human immunodeficiency virus (HIV), Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection; and constitutional symptoms (eg, weight loss, fever, fatigue). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Early signs and symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link&amp;anchor=H1407815786#H1407815786\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\", section on 'Presenting symptoms and signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease should be considered in young children with acute unilateral cervical adenitis associated with fever, rash, conjunctivitis, mucositis, and swelling of the hands and feet. The constellation of symptoms sometimes can be confused with a toxin-mediated",
"    <em>",
"     S. aureus",
"    </em>",
"    or group A streptococcal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     PFAPA syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preschool-aged children with a four- to five-day history of recurrent fevers, aphthous stomatitis, pharyngitis, and cervical adenitis have a benign periodic fever syndrome referred to by its abbreviation, PFAPA (",
"    <strong>",
"     p",
"    </strong>",
"    eriodic",
"    <strong>",
"     f",
"    </strong>",
"    ever,",
"    <strong>",
"     a",
"    </strong>",
"    phthous stomatitis,",
"    <strong>",
"     p",
"    </strong>",
"    haryngitis,",
"    <strong>",
"     a",
"    </strong>",
"    denitis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"     \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Kikuchi disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kikuchi disease is a rare, benign condition of unknown cause usually characterized by cervical lymphadenopathy (although it may be more generalized) and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28647?source=see_link\">",
"     \"Kikuchi's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of swelling in the neck must be distinguished from cervical lymphadenitis. Midline location is one feature that helps to distinguish thyroglossal duct cysts, epidermoid cysts, and lipomas from cervical adenitis since midline lymph nodes are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=see_link\">",
"     \"Thyroglossal duct cysts and ectopic thyroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H41#H41\">",
"     \"The pediatric physical examination: HEENT\", section on 'Neck'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of neck swelling include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Branchial cleft cyst &ndash; Branchial cleft cysts are palpable in the upper portion of the neck, anterior to the sternocleidomastoid muscle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H41#H41\">",
"       \"The pediatric physical examination: HEENT\", section on 'Neck'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystic hygroma &ndash; Cystic hygroma typically presents as a painless soft mass superior to the clavicle and posterior to the sternocleidomastoid muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/17\">",
"       17",
"      </a>",
"      ]. Cystic hygromas may increase in size during upper respiratory tract infection. Transillumination and compressibility help to distinguish cystic hygroma from lymphadenitis.",
"     </li>",
"     <li>",
"      Thyroid tumors &ndash; Thyroid tumors in children usually present as asymptomatic solitary nodules. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=see_link\">",
"       \"Thyroid nodules and cancer in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of neck swelling that appear or are exacerbated during crying or straining include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior mediastinal tumor or cyst &ndash; Superior mediastinal tumors or cysts are associated with widening of the mediastinum on plain radiographs.",
"     </li>",
"     <li>",
"      Laryngocele &ndash; Laryngoceles are outpouchings of the saccular mucosa in the area of the laryngeal ventricle that intermittently fill with air and cause episodic symptoms. They may present as neck masses if they extend through the thyrohyoid membrane. Laryngoceles are visualized as fluid- and air-containing cystic masses on plain radiography, ultrasonography, or computed tomography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital anomalies of the larynx\", section on 'Laryngoceles and saccular cysts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phlebectasia of the jugular vein &ndash; Phlebectasia of the jugular vein is a fusiform or saccular dilation without tortuosity; the diagnosis can be confirmed with color Doppler ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8632/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=see_link\">",
"       \"Patient information: Swollen neck nodes in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are numerous infectious and noninfectious causes of cervical lymphadenitis (",
"      <a class=\"graphic graphic_table graphicRef56712 \" href=\"UTD.htm?6/55/7037\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef77911 \" href=\"UTD.htm?11/21/11612\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical lymphadenitis in children is usually caused by an infectious process. Infectious causes of cervical lymphadenitis frequently are considered in four broad categories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute bilateral cervical lymphadenitis is usually caused by viral upper respiratory infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute bilateral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute unilateral cervical lymphadenitis is usually caused by bacteria.",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      ,",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      (group A streptococcus), and",
"      <em>",
"       Streptococcus agalactiae",
"      </em>",
"      (group B streptococcus) are the most common causes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute unilateral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Subacute/chronic",
"      </span>",
"      bilateral lymphadenitis is usually caused by Epstein-Barr virus or cytomegalovirus. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Subacute/chronic bilateral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Subacute/chronic",
"      </span>",
"      unilateral lymphadenitis is usually caused by nontuberculous mycobacteria infections or",
"      <em>",
"       Bartonella henselae",
"      </em>",
"      , the agent of cat scratch disease (CSD). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Subacute/chronic unilateral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important noninfectious causes of cervical lymphadenopathy include connective tissue disorders, leukemia, lymphoma, Kawasaki disease, periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA), and Kikuchi disease. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Noninfectious causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/1\">",
"      Barton LL, Feigin RD. Childhood cervical lymphadenitis: a reappraisal. J Pediatr 1974; 84:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/2\">",
"      DAJANI AS, GARCIA RE, WOLINSKY E. Etiology of cervical lymphadenitis in children. N Engl J Med 1963; 268:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/3\">",
"      Scobie WG. Acute suppurative adenitis in children: a review of 964 cases. Scott Med J 1969; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/4\">",
"      Baker CJ. Group B streptococcal cellulitis-adenitis in infants. Am J Dis Child 1982; 136:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/5\">",
"      Barton LL, Ramsey RA, Raval DS. Neonatal group B streptococcal cellulitis-adenitis. Pediatr Dermatol 1993; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/6\">",
"      Fluegge K, Greiner P, Berner R. Late onset group B streptococcal disease manifested by isolated cervical lymphadenitis. Arch Dis Child 2003; 88:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/7\">",
"      Brook I. Aerobic and anaerobic bacteriology of cervical adenitis in children. Clin Pediatr (Phila) 1980; 19:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/8\">",
"      Adal KA, Cockerell CJ, Petri WA Jr. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med 1994; 330:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/9\">",
"      Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985; 139:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/10\">",
"      Margileth AM. Cat scratch disease: nonbacterial regional lymphadenitis. The study of 145 patients and a review of the literature. Pediatrics 1968; 42:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/11\">",
"      Marais BJ, Wright CA, Schaaf HS, et al. Tuberculous lymphadenitis as a cause of persistent cervical lymphadenopathy in children from a tuberculosis-endemic area. Pediatr Infect Dis J 2006; 25:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/12\">",
"      Lau SK, Kwan S, Lee J, Wei WI. Source of tubercle bacilli in cervical lymph nodes: a prospective study. J Laryngol Otol 1991; 105:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/13\">",
"      Carvalho AC, Codecasa L, Pinsi G, et al. Differential diagnosis of cervical mycobacterial lymphadenitis in children. Pediatr Infect Dis J 2010; 29:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/14\">",
"      McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987; 9:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/15\">",
"      Payne JH, Evans M, Gerrard MP. Kikuchi-Fujimoto disease: a rare but important cause of lymphadenopathy. Acta Paediatr 2003; 92:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/16\">",
"      Lee KY, Yeon YH, Lee BC. Kikuchi-Fujimoto disease with prolonged fever in children. Pediatrics 2004; 114:e752.",
"     </a>",
"    </li>",
"    <li>",
"     Healy CM, Baker CJ. Cervical lymphadenitis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/18\">",
"      MOUSSATOS GH, BAFFES TG. CERVICAL MASSES IN INFANTS AND CHILDREN. Pediatrics 1963; 32:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/19\">",
"      Wieringa JW, van Houten MA. Case 2: A crying patient with a swelling in the neck. Phlebectasia of the external jugular vein. Acta Paediatr 2008; 97:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/20\">",
"      Balik E, Erdener A, Taneli C, et al. Jugular phlebectasia in children. Eur J Pediatr Surg 1993; 3:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/21\">",
"      Sander S, Eli&ccedil;evik M, Unal M, Vural O. Jugular phlebectasia in children: is it rare or ignored? J Pediatr Surg 1999; 34:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/22\">",
"      Turan-Ozdemir S, Coskun H, Balban M. Phlebectasia of the external jugular vein associated with duplication of the internal jugular vein. Clin Anat 2004; 17:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8632/abstract/23\">",
"      Paleri V, Gopalakrishnan S. Jugular phlebectasia: theory of pathogenesis and review of literature. Int J Pediatr Otorhinolaryngol 2001; 57:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5982 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8632=[""].join("\n");
var outline_f8_27_8632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infectious",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Noninfectious",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACUTE BILATERAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Viral URI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Group A streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE UNILATERAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      S. aureus and GAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Group B streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anaerobic bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUBACUTE/CHRONIC BILATERAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EBV and CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUBACUTE/CHRONIC UNILATERAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10472015\">",
"      NTM infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NONINFECTIOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Connective tissue disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neoplasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PFAPA syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Kikuchi disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5982|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19285\" title=\"figure 1\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5982|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/6/18542\" title=\"picture 1\">",
"      Staphylococcal adenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/19/5439\" title=\"picture 2\">",
"      Tularemia adenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/60/41934\" title=\"picture 3\">",
"      Mycobacterium avium adenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34814\" title=\"picture 4\">",
"      Enlarged lymph node in cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/60/8128\" title=\"picture 5\">",
"      Cat scratch disease typical papular lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/62/31723\" title=\"table 1\">",
"      Lymphatic drainage of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/55/7037\" title=\"table 2\">",
"      Infectious causes of cervical nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/21/11612\" title=\"table 3\">",
"      Noninfectious causes of cervical nodes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14166?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28647?source=related_link\">",
"      Kikuchi's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=related_link\">",
"      The common cold in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=related_link\">",
"      Thyroid nodules and cancer in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27768?source=related_link\">",
"      Tuberculous lymphadenitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8633="Medical management of immune deficiency";
var content_f8_27_8633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of immune deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8633/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8633/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/27/8633/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical consequence of immune deficiency is an increased frequency and severity of infection. As understanding of the molecular defects underlying many of these disorders continues to expand, a number of new medical therapies have provided dramatic improvements in life expectancy and in the quality of life for immune deficient and immune suppressed subjects.",
"   </p>",
"   <p>",
"    The use of medical therapies, including immune globulin, vaccination, and prophylactic antibiotics, in the treatment of immune deficiency will be reviewed here. Practical measures for avoiding infection are also discussed. The suggestions in this topic review are consistent with practice parameters for the management of primary immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of hematopoietic cell transplantation and the possible role of gene therapy in the treatment of primary immune deficiencies, and additional information regarding therapies for specific disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection and diagnosis of primary immunodeficiency improves clinical outcomes. There are various measures that can help identify immunodeficiencies promptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Detecting severe primary immunodeficiencies in neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is available for a growing number of primary immunodeficiencies and neonatal screening for various forms of severe combined immunodeficiency (SCID) is available in some states in the United States (US) and some other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Identification of neonates with SCID is particularly critical and newborns known to have, or who are at high risk for SCID, should be isolated and carefully managed from birth. Neonatal screening, initial testing, isolation, and perinatal management for SCID are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H11#H11\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chest x-ray to detect the absence of a thymic shadow is a useful and quick screening test for SCID. The only forms of SCID in which a thymus shadow is present on a chest x-ray at birth are those caused by a deficiency of the delta chain of the CD3 complex, ZAP-70 deficiency, and coronin 1A deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"       \"Severe combined immunodeficiency (SCID): An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"       \"ZAP-70 deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A CBC with differential at birth is also useful, since &gt;95 percent of patients with SCID have severe lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/6\">",
"       6",
"      </a>",
"      ]. A total lymphocyte count &lt;2500 is strongly suggestive of lymphopenia in newborns. Some infants with primary immunodeficiency have severe neutropenia or thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cord blood should be studied for lymphocyte numbers and in vitro function. Flow cytometry is often diagnostic since the great majority of patients have very low numbers of T cells (and absence of naive T cells) in the peripheral circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Infants with agammaglobulinemia have very low or absent B cells. In vitro functional tests of T cells, such as mitogen response, are abnormal in all cases of SCID. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"       \"Laboratory evaluation of the immune system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link\">",
"       \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ongoing emigration of newly developing T cells from the thymus can be measured by determining the number of T cell receptor excision circles (TRECs) in peripheral blood. Quantitation of TRECs as part of the newborn screen may be useful in identifying infants with SCID who are not already known to be at risk [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. Interpretation of TREC numbers is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"       \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determination of antibody levels in newborns is generally",
"      <strong>",
"       not",
"      </strong>",
"      helpful, since IgG is mostly maternal in origin, and IgA and IgM levels are low in normal newborns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Wherever possible, molecular studies should be pursued if standard phenotypic and functional testing cannot establish a specific diagnosis. Determining the nature of the defect at the molecular level, and discerning whether the mutation is new (ie, sporadic) or inherited allows accurate genetic counseling and prenatal testing in the case of future pregnancies. This information permits parents to choose to terminate pregnancies that are affected by or at high risk for a particular defect. For pregnancies that are continued, in utero testing permits preparation for hematopoietic cell transplantation (HCT) in the neonatal period if indicated, or possibly in utero. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Banking cord blood is suggested, either for use in future gene therapy if the infant is affected, or for future transplant of an existing or potential affected sibling if the infant is unaffected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLA typing should be undertaken as soon as a diagnosis of SCID or other immune deficiency potentially correctable by hematopoietic cell transplantation is established. The risks of HCT are reduced in patients who have not yet developed infectious complications of immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Furthermore, the thymus microenvironment may deteriorate over time and be less capable of supporting T cell development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Detecting primary immunodeficiency in children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many forms of primary immunodeficiency do not have overt clinical manifestations until well after the newborn period or even in adulthood. Delay in diagnosis is an important contributor to morbidity and mortality at any age. The Jeffrey Modell Foundation has developed \"10 Warning Signs\" of primary immunodeficiency which are intended to raise awareness of possible immunodeficiency in health care providers and in patients and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 10 Warning Signs are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four or more new ear infections within one year",
"     </li>",
"     <li>",
"      Two or more serious sinus infections within one year",
"     </li>",
"     <li>",
"      Two or more months on antibiotics with little effect",
"     </li>",
"     <li>",
"      Two or more pneumonias within one year",
"     </li>",
"     <li>",
"      Failure of an infant to gain weight or grow normally",
"     </li>",
"     <li>",
"      Recurrent, deep skin or organ abscesses",
"     </li>",
"     <li>",
"      Persistent thrush in mouth or elsewhere on skin, after age one",
"     </li>",
"     <li>",
"      Need for intravenous antibiotics to clear infections",
"     </li>",
"     <li>",
"      Two or more deep-seated infections",
"     </li>",
"     <li>",
"      A family history of primary immunodeficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of a child or adult with recurrent infections is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of secondary immune deficiency arise as complications of medical therapies in solid organ transplantation, HCT, and malignant and autoimmune disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"     \"Secondary immune deficiency due to miscellaneous causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with secondary immunodeficiency, disturbed immune function may be an anticipated cost of treatment and may not be preventable. Thus, most protocols for the care of such patients include routine monitoring of various aspects of immune function and prophylactic regimens against infection. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tests of immune function that can be obtained through a general clinical laboratory are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REFERRAL AND RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinician with experience in diagnosing and treating immunodeficiency must be involved early to assist in specific diagnosis and to formulate an ongoing plan of care. Regular follow-up (eg, at least annual) with such a clinician is also recommended.",
"   </p>",
"   <p>",
"    Periodic evaluation may include monitoring of immune and general hematologic and metabolic parameters, lung function, and imaging. The specific studies to be performed depend on the particular diagnosis, treatment, and complications. These are discussed individually for specific disorders. The Immune Deficiency Foundation has a Consulting Immunologist Program (CIP) to connect health care providers who have questions about patients with known or suspected immunodeficiency with clinicians experienced in diagnosing and managing these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients and families with primary immunodeficiency may benefit from networks of other patients and care providers, which can provide useful information regarding social and emotional support, negotiating the health care system and third party payers, and other issues. Several organizations have internet web sites for these purposes.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American Academy of Allergy, Asthma, and Immunology (AAAAI) (",
"      <a class=\"external\" href=\"file://www.aaaai.org\">",
"       www.aaaai.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary Immunodeficiency Resource Center (",
"      <a class=\"external\" href=\"file://www.info4pi.org/\">",
"       www.info4pi.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Jeffrey Modell Foundation (JMF) (",
"      <a class=\"external\" href=\"file://www.jmfworld.org/\">",
"       www.jmfworld.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Immune Deficiency Foundation (",
"      <a class=\"external\" href=\"file://www.primaryimmune.org/\">",
"       www.primaryimmune.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Avoidance of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the goals of medical therapy is to provide the greatest possible function and integration into society. Children and adults with mild forms of immune deficiency should be encouraged to participate in all usual activities. Normal school attendance should be the goal for children with immunodeficiency, although some experts advise against the placement of infants and young children in large institutional daycare settings where there is a well-documented higher rate of infectious illness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Similar considerations also apply to adults in whom placement in institutional settings is a consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several routine measures patients and families can take to reduce exposure to others with potentially contagious illnesses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instructions in proper hand washing and use of alcohol-based disinfectants should be provided to patients and their families. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H3#H3\">",
"       \"General principles of infection control\", section on 'Hand hygiene'",
"      </a>",
"      .) Patient information is available in topics about avoidance of the common cold. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=see_link\">",
"       \"Patient information: The common cold in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=see_link\">",
"       \"Patient information: The common cold in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Co-sleeping among family members should be minimized, and immunization of family members and close contacts (against influenza, for example) is encouraged.",
"     </li>",
"     <li>",
"      Careful attention should be paid to patient&rsquo;s oral hygiene and dental health.",
"     </li>",
"     <li>",
"      Drinking water may be an issue for immunocompromised patients. Private wells and public sources may be contaminated with giardia or cryptosporidium. The latter is resistant to chlorination. Some advocate use of filtration systems or bottled water, although this issue has not been extensively investigated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immune globulin replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin therapy is used in a variety of primary immunodeficiency disorders, including primary antibody deficiencies, combined immunodeficiencies prior to transplantation and until B cell function is restored, and other specific disorders involving defects in antibody production or function. Specific indications and a detailed discussion of the use of immune globulin therapy are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specialized immune globulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum from donors having high titers of antibodies directed against particular infectious organisms may be pooled to prepare special lots of immune globulin with standardized amounts of antibody activity against the pathogen in question, or \"hyperimmune globulins\" (",
"    <a class=\"graphic graphic_table graphicRef73892 \" href=\"UTD.htm?34/10/34988\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cytomegalovirus immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;CytoGam (MedImmune, Inc., Gaithersburg, MD) is a gamma globulin preparation using pooled serum from donors with high titers of cytomegalovirus (CMV) antibody. It has been used principally for the prophylaxis of CMV infection in immune suppressed recipients of solid organ transplants (eg, kidney, lung) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/20\">",
"     20",
"    </a>",
"    ]. However, this has largely been replaced in these patients by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . Cytogam is still used as an adjunct to antiviral drugs in some immunocompromised patients with CMV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Varicella-zoster immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella virus is capable of causing severe disease in immunocompromised adults and children. Patients who are receiving regular infusions of immune globulin are protected and do not require further passive prophylaxis for varicella exposure. In contrast, seronegative adults, or those with no history of infection, may be given varicella-zoster immune globulin (VariZIG, Cangene, Corp.). In such patients, postexposure prophylaxis should be administered within 96 hours of close contact with an individual with varicella infection (",
"    <a class=\"graphic graphic_table graphicRef73892 \" href=\"UTD.htm?34/10/34988\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolation is recommended for any patient with varicella. For immunocompetent patients, a minimum of five days after the appearance of the rash, as long as it remains vesicular, is the recommended period. This corresponds to the time of maximum contagiousness. The rash may remain vesicular longer in immunocompromised hosts, requiring a longer period of isolation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Palivizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synagis (MedImmune, Inc.) is a humanized monoclonal anti-RSV antibody used for prevention of respiratory syncytial virus (RSV) infection in certain high risk groups. It may be administered for this purpose to patients with primary or secondary immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104278856#H104278856\">",
"     \"Respiratory syncytial virus infection: Prevention\", section on 'Immunoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other immune serum globulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other immunoglobulin products are formulated for the prevention of specific infections following certain high-risk exposures. These include (",
"    <a class=\"graphic graphic_table graphicRef73892 \" href=\"UTD.htm?34/10/34988\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       Tetanus immune globulin",
"      </a>",
"      (TIG, HyperTET",
"      <span class=\"nowrap\">",
"       S/D,",
"      </span>",
"      Talecris Biotherapeutics Inc.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       Hepatitis B immune globulin",
"      </a>",
"      (HBIG, HepaGam-B, Cangene Corp.; HyperHEP B",
"      <span class=\"nowrap\">",
"       S/D,",
"      </span>",
"      Talecris Biotherapeutic, Inc.; Nabi-HB, Nabi Biopharmaceuticals Inc.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/22/6500?source=see_link\">",
"       Human rabies immune globulin",
"      </a>",
"      (HRIG, HyperRAB",
"      <span class=\"nowrap\">",
"       S/D,",
"      </span>",
"      Talecris Biotherapeutics Inc.; Imogam Rabies-HT, Sanofi-Pasteur Inc.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/33/6677?source=see_link\">",
"       Vaccinia immune globulin",
"      </a>",
"      (VIG-IV, Cangene Corp., for complications of smallpox immunization)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two questions typically arise concerning vaccination of immunocompromised patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Will the patient make a sufficient response to the vaccine to justify its use?",
"     </li>",
"     <li>",
"      Could the patient be harmed by administration of a live viral or bacterial vaccine?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vaccines that are recommended by the US Centers for Disease Control (CDC) for patients with different categories of primary immunodeficiency diseases are reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"     21",
"    </a>",
"    ]. Guidelines for patients with secondary immunodeficiency are also provided (",
"    <a class=\"graphic graphic_table graphicRef69376 \" href=\"UTD.htm?7/15/7421\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    The accompanying tables summarize other related recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine immunizations in immunocompromised children (",
"      <a class=\"graphic graphic_table graphicRef72390 \" href=\"UTD.htm?22/0/22541\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Routine immunizations in immunocompromised adults (",
"      <a class=\"graphic graphic_table graphicRef50377 \" href=\"UTD.htm?26/48/27405\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonroutine immunizations in immunocompromised patients (",
"      <a class=\"graphic graphic_table graphicRef63112 \" href=\"UTD.htm?21/52/22349\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More detailed discussions of immunizations in patients with specific causes of secondary immunodeficiency are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Killed or subcomponent vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Killed or subcomponent vaccines have no risk beyond what is encountered in immunocompetent individuals. Therefore, routine immunization schedules should be followed wherever vaccinations offer possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. In addition, patients known to be at risk with respect to particular infectious agents should be immunized wherever possible (",
"    <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with specific disorders may not respond fully to vaccines. As examples, one study of 26 patients with humoral primary immunodeficiencies given the trivalent influenza vaccine found that only 29 percent had a significant increase in titer and 83 percent attained protective levels, compared to 77 and 100 percent, respectively, of healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/23\">",
"     23",
"    </a>",
"    ]. Impaired antibody responses to trivalent influenza were also reported in 23 patients with rheumatoid arthritis receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the general advice remains to vaccinate if there is possible benefit to the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Live vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of live vaccines varies with the degree of immune deficiency. Severe immune deficiency can result from primary immunodeficiency, HIV infection, or secondary immunosuppression due to generalized malignancy, leukemia, lymphoma, aplastic anemia, or therapy with alkylating agents, antimetabolites, radiation, or large doses of glucocorticoids (eg, &gt;than 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 40 mg daily for more than two weeks) (",
"    <a class=\"graphic graphic_table graphicRef72390 \" href=\"UTD.htm?22/0/22541\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50377 \" href=\"UTD.htm?26/48/27405\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine live vaccines",
"      <span class=\"nowrap\">",
"       measles/mumps/rubella",
"      </span>",
"      (MMR) vaccine, intranasal influenza vaccine (eg, FluMist), BCG, rotavirus (eg, RotaTeq), and oral polio virus (OPV) should",
"      <strong>",
"       not",
"      </strong>",
"      be administered to patients with severe immune deficiencies, as the vaccine can lead to disseminated infection [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. One exception may be the administration of",
"      <span class=\"nowrap\">",
"       measles/mumps/rubella",
"      </span>",
"      (MMR) vaccine to some patients with HIV infection (",
"      <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69376 \" href=\"UTD.htm?7/15/7421\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"       \"Immunizations in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients treated with regular infusions of immune globulin have protective titers to most common vaccine agents (eg, measles) and are at least partly protected from these diseases. Commercial IgG preparations contain significant neutralizing antibody to common attenuated vaccine viruses such as MMR and varicella, rendering such vaccines inactive. Most experts do not administer routine vaccines, except against pathogens to which there is little antibody in the plasma donor pool (eg, influenza) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Live vaccines used in specific circumstances, such as those for vaccinia (small pox), typhoid (Ty21a), and yellow fever, should also be avoided in patients with severe immunocompromise (",
"      <a class=\"graphic graphic_table graphicRef63112 \" href=\"UTD.htm?21/52/22349\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Healthy household contacts of immunocompromised individuals should not be given oral polio vaccine (OPV) because of the possibility of transmission. In contrast, they can be given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      and MMR vaccine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with mild antibody deficiencies, or those with phagocyte or complement defects receiving only antibiotic prophylaxis, may receive all vaccines, including live vaccines (",
"      <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Decisions regarding patients with particularly mild forms of combined deficiencies, such as ataxia-telangiectasia, or DiGeorge syndrome, should be made on a case-by-case basis, depending upon the level of cellular and antibody function, and the risks of remaining unimmunized (",
"      <a class=\"graphic graphic_table graphicRef55584 \" href=\"UTD.htm?35/6/35949\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"       \"DiGeorge syndrome: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized approach to the use of prophylactic antibiotics in patients with immunodeficiency. Rigorous studies of the efficacy of antibiotic prophylaxis in specific immune disorders are lacking, with a few notable exceptions (eg, chronic granulomatous disease). A survey of American immunologists reported that, in the absence of consensus guidelines, approximately 75 percent of practitioners administered prophylactic antibiotics to at least some of their immunodeficiency patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/28\">",
"     28",
"    </a>",
"    ]. In most cases, this practice is intended to reduce the frequency and severity of sinopulmonary infections caused by common bacteria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic prophylaxis is most consistently offered to patients with mild hypogammaglobulinemia, IgA deficiency, or IgG subclass deficiency, who are not receiving immune globulin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. This therapy is sometimes administered for relatively short periods of time (eg, over the winter) for a few years.",
"     </li>",
"     <li>",
"      Patients with more severe antibody deficiencies receiving immune globulin may have an increased rate of bacterial infections chronically or at certain times of the year (eg, during the winter) and may also benefit from antibiotic prophylaxis. However, there are no published controlled studies of the benefits of antibiotic prophylaxis in patients receiving immune globulin replacement therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Representative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens of antibacterial prophylaxis applied in the care of immune deficient patients were initially derived from a series of immunocompetent patients with recurrent otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. A general principal is the use of approximately one-half of a therapeutic dose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as a single dose or divided BID); or sulfisoxazole (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as a single dose); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      as a single dose); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week).",
"      <br/>",
"      <br/>",
"      If these options are not effective,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as a single dose) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kd",
"      </span>",
"      per day as a single dose or divided BID) can be used.",
"     </li>",
"     <li>",
"      For adults &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg daily or 250 to 500 mg twice daily); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (160 mg as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      daily or 80 to 160 mg twice daily); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg per week.",
"      <br/>",
"      <br/>",
"      If these options are not effective,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (500 mg per day); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      (875 mg or 1000 mg per day in a single dose) can be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At some centers, it is common practice to \"rotate\" or periodically change antibiotics to avoid the development of resistance to a specific drug [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/28\">",
"     28",
"    </a>",
"    ]. The frequency with which antibiotics are rotated varies from monthly to every six months. However, studies have not been performed to compare rotation to the use of one agent for an extended period of time, and so the best approach is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prevention of P jirovecii pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis for Pneumocystis jirovecii (carinii) pneumonia should be administered to patients with severe combined immune deficiencies and patients receiving potent immunosuppressive therapy.",
"   </p>",
"   <p>",
"    PCP prophylaxis is also indicated in some other immunodeficiencies, such as X-linked hyper-IgM syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    ). Prophylactic regimens for PCP in primary and secondary immune deficiency are similar to those administered to patients with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected or known T cell immunodeficiencies should not be given blood or blood components that may contain viable lymphocytes because of the risk of fatal graft-versus-host disease. This applies mainly to SCID, and other forms of immune deficiency where T cell function may be severely compromised, eg, Wiskott-Aldrich syndrome, X-linked hyper-IgM syndrome, NEMO deficiency, and complete DiGeorge syndrome (and others). Any cellular blood products given to these patients must be irradiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood products should also be tested for cytomegalovirus (CMV), a virus that can cause significant disease in immunocompromised individuals who have an underlying T cell defect or are status-post transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\", section on 'CMV infections in immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Audiologic care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensorineural hearing loss occurs in a relatively high percentage of children with primary antibody deficiencies. One study found that 38 percent of a group of 47 children with either X-linked or autosomal recessive agammaglobulinemia or common variable immunodeficiency had hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8633/abstract/34\">",
"     34",
"    </a>",
"    ]. Possible contributing factors include recurrent bacterial otitis media, exposure to neurotoxic antibiotics, certain viral infections, and CNS infections. Audiologic evaluation should be considered in children with antibody disorders, to maximize educational and interpersonal functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of patients with primary immune deficiency begins with early identification and diagnosis. Families with affected children require counseling about the risk of the same disorder occurring in future children. If an affected pregnancy is identified, measures to prevent infection and plan for curative therapies begin at birth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Detecting severe primary immunodeficiencies in neonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Detecting primary immunodeficiency in children and adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary immunodeficiency usually arises as a complication of medical therapies in solid organ transplantation, hematopoietic cell transplantation, and malignant and autoimmune disease. Immune function should be monitored as part of the administration of these therapies, so that infections can be anticipated and prevented when possible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Secondary immunodeficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to prevent routine infections include education of the patient and caregivers about effective hand hygiene, meticulous attention to oral and dental care, caution with drinking water, and avoidance of regular exposure to large groups of people in institutional environments, such as large day cares and group homes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Avoidance of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immune globulin replacement is important in the management of primary antibody deficiencies, combined immunodeficiencies prior to transplantation and until B cell function is restored, and other specific disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with immunodeficiency can safely receive all killed or inactivated vaccines. In contrast, live vaccines should",
"      <strong>",
"       not",
"      </strong>",
"      be given to patients with severe immune dysfunction and, in the case of oral polio vaccine, should not be given to household contacts of the patient either. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effectiveness of prophylactic antibiotics in preventing infection in patients with specific immunodeficiency disorders, choice of agent, dose and schedule are not well studied, and practices differ widely.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      at lower than therapeutic doses are commonly used. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/1\">",
"      Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1.",
"     </a>",
"    </li>",
"    <li>",
"     A world database of laboratories performing genetic testing for immunodeficiencies may be found at: file://bioinf.uta.fi/IDdiagnostics/index_IDs.php?page=index/service (Accessed on December 17, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/3\">",
"      Baker MW, Grossman WJ, Laessig RH, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol 2009; 124:522.",
"     </a>",
"    </li>",
"    <li>",
"     Contact information for laboratories that provide genetic testing services is available through the GeneTests website: www.geneclinics.org (Accessed on December 17, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/5\">",
"      Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003; 349:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/6\">",
"      Kalman L, Lindegren ML, Kobrynski L, et al. Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review. Genet Med 2004; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/7\">",
"      Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/8\">",
"      McGhee SA, Stiehm ER, Cowan M, et al. Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Mol Genet Metab 2005; 86:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/9\">",
"      Griffith LM, Cowan MJ, Kohn DB, et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008; 122:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/10\">",
"      Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005; 115:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/11\">",
"      Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant 2008; 42 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/12\">",
"      Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990; 336:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/13\">",
"      Buckley RH. A historical review of bone marrow transplantation for immunodeficiencies. J Allergy Clin Immunol 2004; 113:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/14\">",
"      Buckley RH, Schiff SE, Schiff RI, et al. Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Semin Hematol 1993; 30:92.",
"     </a>",
"    </li>",
"    <li>",
"     Available through the Primary Immunodeficiency Resource Center. www.info4pi.org (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     The CIP can be contacted at the following URL. file://www.primaryimmune.org/healthcare/immunologist_prog.asp (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/17\">",
"      Schwartz B, Giebink GS, Henderson FW, et al. Respiratory infections in day care. Pediatrics 1994; 94:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/18\">",
"      Wald ER, Guerra N, Byers C. Frequency and severity of infections in day care: three-year follow-up. J Pediatr 1991; 118:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/19\">",
"      Beck-Sague C, Villarino E, Giuliano D, et al. Infectious diseases and death among nursing home residents: results of surveillance in 13 nursing homes. Infect Control Hosp Epidemiol 1994; 15:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/20\">",
"      Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/21\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/22\">",
"      Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/23\">",
"      van Assen S, Holvast A, Telgt DS, et al. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol 2010; 136:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/24\">",
"      Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/25\">",
"      Ghaffar F, Carrick K, Rogers BB, et al. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000; 19:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/26\">",
"      Hidalgo S, Garc&iacute;a Erro M, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J 2003; 22:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/27\">",
"      Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/28\">",
"      Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010; 135:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/29\">",
"      Herrod HG. Management of the patient with IgG subclass deficiency and/or selective antibody deficiency. Ann Allergy 1993; 70:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/30\">",
"      Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2009; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/31\">",
"      Liston TE, Foshee WS, Pierson WD. Sulfisoxazole chemoprophylaxis for frequent otitis media. Pediatrics 1983; 71:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/32\">",
"      Principi N, Marchisio P, Massironi E, et al. Prophylaxis of recurrent acute otitis media and middle-ear effusion. Comparison of amoxicillin with sulfamethoxazole and trimethoprim. Am J Dis Child 1989; 143:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/33\">",
"      De Diego JI, Prim MP, Alfonso C, et al. Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media. Int J Pediatr Otorhinolaryngol 2001; 58:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8633/abstract/34\">",
"      Berlucchi M, Soresina A, Redaelli De Zinis LO, et al. Sensorineural hearing loss in primary antibody deficiency disorders. J Pediatr 2008; 153:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3948 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8633=[""].join("\n");
var outline_f8_27_8633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Detecting severe primary immunodeficiencies in neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Detecting primary immunodeficiency in children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REFERRAL AND RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Avoidance of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immune globulin replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specialized immune globulins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cytomegalovirus immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Varicella-zoster immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Palivizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other immune serum globulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Killed or subcomponent vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Live vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Representative regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prevention of P jirovecii pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Blood products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Audiologic care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/10/34988\" title=\"table 1\">",
"      Summary ACIP recs IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/6/35949\" title=\"table 2\">",
"      Vaccination in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/15/7421\" title=\"table 3\">",
"      Vaccination in secondary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/0/22541\" title=\"table 4\">",
"      Summary ACIP recs I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/48/27405\" title=\"table 5\">",
"      Summary ACIP recs II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/52/22349\" title=\"table 6\">",
"      Summary ACIP recs III",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=related_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=related_link\">",
"      ZAP-70 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8634="Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction";
var content_f8_27_8634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8634/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8634/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8634/contributors\">",
"     J Brent Muhlestein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8634/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8634/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8634/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/27/8634/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/27/8634/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/27/8634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary reperfusion with fibrinolysis or primary percutaneous coronary intervention (PCI) substantially improves survival in patients with an acute ST elevation (Q wave) myocardial infarction (STEMI) compared to no reperfusion therapy. Primary PCI is preferred for most patients if it can be performed by an experienced operator with less than a 90 minute delay from presentation to the emergency department. However, fibrinolysis remains an important therapeutic modality, due in part to limited availability of primary PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principle reason for the preference of PCI to fibrinolysis is the relatively high frequency of failure of fibrinolysis to establish reperfusion (primary failure). In addition early reocclusion occurs in a significant number of cases. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Primary failure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Threatened reocclusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Primary failure of fibrinolysis is often manifested clinically by persistent or worsening chest pain (particularly if associated with other symptoms such as dyspnea and diaphoresis), persistent or worsening ST segment elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic instability or heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/1\">",
"     1",
"    </a>",
"    ]. However, these clinical factors are not sufficiently predictive in all patients. As a result, in the absence of clear indications of reperfusion, the clinician must maintain a high index of suspicion for primary failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/2\">",
"     2",
"    </a>",
"    ]. Additionally, in patients who undergo diagnostic angiography after fibrinolysis, both TIMI",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    and TIMI 2 flow are associated with increased mortality compared to those with TIMI 3 (normal) flow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis of primary failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These observations have provided the rationale for immediate angiography with intent to perform rescue percutaneous intervention (PCI), as well as routine early elective angiography one to two days after fibrinolysis. However, angiography in the first two hours after fibrinolytic therapy, when bleeding risks are higher, is reserved for patients with overt evidence of failed fibrinolysis. The use of routine angiography after fibrinolysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H15#H15\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Adjunctive or early elective PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If initial fibrinolysis fails to establish reperfusion or if threatened reocclusion occurs, further efforts to achieve reperfusion should be attempted. This topic will review the roles of angiography followed by PCI (or coronary artery bypass graft surgery if indicated) for failed fibrinolysis or threatened reocclusion and of retreatment with fibrinolytic drugs for threatened reocclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Importance of restoration of normal flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome after fibrinolytic therapy in patients with an STEMI is related to the degree to which flow has been restored in the infarct-related artery. In the cardiac catheterization laboratory, patency of the infarct-related artery is usually graded according to the TIMI classification system. In clinical trials of fibrinolysis, patency is usually measured at 60 to 90 minutes after the administration of fibrinolytic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TIMI 0 refers to the absence of any antegrade flow beyond a coronary occlusion",
"     </li>",
"     <li>",
"      TIMI 1 flow is faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete",
"     </li>",
"     <li>",
"      TIMI 2 flow is delayed or sluggish antegrade flow with complete filling of the distal territory",
"     </li>",
"     <li>",
"      TIMI 3 flow is normal flow which fills the distal coronary bed completely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only TIMI 3 (normal) flow is associated with a mortality benefit after fibrinolysis (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a meta-analysis of five trials of almost 4000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/4\">",
"     4",
"    </a>",
"    ]. Short-term mortality (in-hospital to 30 days in the different trials) was 3.7, 7.0, and 8.8 percent among patients with TIMI grade 3, 2, and",
"    <span class=\"nowrap\">",
"     0/1,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Restoration of TIMI 3 flow is also associated with better left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The possible reasons why worse outcomes are seen with TIMI 2 flow are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis of primary failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major problem in implementing a therapeutic strategy for primary failed fibrinolysis is identification of appropriate candidates for intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/9\">",
"     9",
"    </a>",
"    ]. In clinical trials, the efficacy of fibrinolysis is often assessed with angiography performed 60 to 90 minutes after fibrinolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary failure is usually defined as persistent occlusion of the infarct-related artery (TIMI grade",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      epicardial flow). In the meta-analysis cited above, TIMI grade",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      occurred in 27 percent and was associated with a higher short-term mortality rate than TIMI 3 flow (8.8 versus 3.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/4\">",
"       4",
"      </a>",
"      ]. Since mortality is also increased in patients with TIMI 2 flow, some have also considered TIMI 2 a sign of failed fibrinolysis and some trials of rescue therapies have enrolled such patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'TIMI grade 2 flow'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In addition to patency of the epicardial coronary arteries, adequacy of microvascular flow, as determined by the myocardial perfusion grade, can also be assessed during angiography. Myocardial perfusion grade may also be an important predictor of long-term benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical practice, routine angiography is not recommended in the first hours after fibrinolysis solely for the purpose of assessing the efficacy of therapy. Angiography and PCI are appropriate for the treatment, but not the diagnosis, of failed fibrinolysis.",
"   </p>",
"   <p>",
"    In the absence of routine angiography, clinical factors such as chest pain, hemodynamic status, changes in serum markers of MI, and the course of ST segment elevation have been used to estimate the likelihood of failed fibrinolysis or of successful reperfusion. Both the 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    and the 2009 European Society of Cardiology guidelines on STEMI considered a reduction of at least 50 percent of the initial ST segment elevation on a follow-up ECG 60 to 90 minutes after fibrinolytic therapy to be suggestive of reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H7#H7\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'ST segment elevation resolution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary failure of fibrinolysis is often suspected clinically by persistent or worsening chest pain (particularly if associated with other symptoms such as dyspnea and diaphoresis), persistent or worsening ST segment elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic instability or heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these parameters do not predict failed fibrinolysis in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. Chest pain alone is subjective, especially if improved, and many patients do not have complete ST segment elevation resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. In addition, ST segment elevation resolution and patency of the infarct-related artery are not always correlated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H9#H9\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Resolution and artery patency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential lack of correlation between ST segment elevation and TIMI flow grade was illustrated in the TIMI 14 trial of 444 patients with an interpretable ECG who underwent angiography at 90 minutes after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. TIMI 3 flow was present in only 79 percent of patients with complete (&ge;70 percent) ST segment resolution and was also present in 44 to 50 percent of patients with partial or no ST segment resolution. The latter patients were at increased risk for mortality, as the lack of complete ST segment resolution was presumably due to extensive microvascular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis of threatened reocclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Threatened reocclusion is characterized by the development of early recurrent ischemia after apparently successful fibrinolysis. Thrombotic coronary reocclusion can be manifested by recurrent ST segment changes or recurrent chest pain, and may or may not be accompanied by biomarker evidence of reinfarction. The clinical and angiographic predictors of reocclusion, including a possible contribution from fibrinolysis itself, and possible methods of prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20759?source=see_link\">",
"     \"Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After apparently successful fibrinolysis by clinical criteria, early recurrence of ischemia or ST segment shifts (threatened reocclusion) has been observed in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], thrombotic coronary reocclusion in 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/6,21,22\">",
"     6,21,22",
"    </a>",
"    ], and reinfarction in 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. In two reviews of almost 76,000 patients from GUSTO-I, GUSTO-III, and the TIMI and InTIME II trials, reinfarction occurred in 4.3 percent of patients at a median of two to four days after fibrinolytic therapy and was independent of the fibrinolytic agent used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force recommended some specific guidelines for the diagnosis of reinfarction after an acute STEMI and no changes to this approach were made in the 2007 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within the first 18 hours of the initial MI, a recurrent elevation in cardiac biomarkers alone should",
"      <strong>",
"       not",
"      </strong>",
"      be relied upon to diagnose reinfarction, but should be accompanied by recurrent ST segment elevation on ECG and at least one other supporting criterion (such as recurrent chest pain or hemodynamic decompensation).",
"     </li>",
"     <li>",
"      For patients more than 18 hours from the initial MI, a biomarker rise of at least 50 percent and at least one additional criterion are sufficient for the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with coronary reocclusion have a worse 30 day and one year mortality compared to those without [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/20,22-25\">",
"     20,22-25",
"    </a>",
"    ]. As will be described below, the mortality associated with reinfarction can be markedly reduced with PCI during the index hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reinfarction in a new territory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in patients with an acute coronary syndrome have demonstrated multiple unstable plaques within the coronary circulation. Thus, reinfarction might occur in a new territory rather than reflecting failed fibrinolysis in the index territory.",
"   </p>",
"   <p>",
"    This issue was addressed in a report from the HERO-2 trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    versus unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prior to streptokinase administration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/27\">",
"     27",
"    </a>",
"    ]. Confirmed reinfarction occurred in 552 patients (3.2 percent). Among these patients, 67 percent had ST elevation in the index territory, 18 percent had no new ECG changes, 2 percent had new bundle branch block, and 4 percent (0.15 percent of all patients) had ST elevation in a new territory at a mean of 46 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIMARY FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary failure is best treated with immediate PCI. Patients should be referred to a facility with PCI capability soon after fibrinolysis in most cases so that failed fibrinolysis can be managed expeditiously. This strategy will avoid the need to consider repeat lysis except in rare cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rescue PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rescue or salvage percutaneous coronary intervention (PCI) is defined as PCI performed within 12 hours of failed fibrinolysis (primary failure) in patients with evidence of continuing or recurrent myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/11\">",
"     11",
"    </a>",
"    ]. Several older, nonrandomized studies and a number of randomized trials, including RESCUE, MERLIN, and REACT, evaluated the role of rescue PCI after primary failed fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/1,28-30\">",
"     1,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2007 meta-analysis of six trials (including RESCUE and MERLIN) that randomly assigned 908 patients to rescue PCI or conservative therapy and had follow-up between hospital discharge and six months demonstrated the following benefits of rescue PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a trend toward lower all-cause mortality (relative risk 0.68, 95% CI 0.46-1.05) that failed to reach statistical significance.",
"     </li>",
"     <li>",
"      There were significant reductions in the relative risk (RR 0.73; 95% CI 0.54-1.00) and absolute risk of developing heart failure (5 percent; 95% CI 0-9).",
"     </li>",
"     <li>",
"      There was a significant reduction in the risk of reinfarction (RR 0.58; 95% CI 0.35-0.97)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these findings may underestimate the benefit of rescue PCI since all of the patients who underwent PCI in RESCUE and half of the patients in MERLIN, received percutaneous transluminal coronary angioplasty (PTCA) without stenting. The potential importance of stenting in this setting was demonstrated in the STOPAMI-4 trial, which compared angioplasty to stenting in 181 patients with failed fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/2\">",
"     2",
"    </a>",
"    ]. Stenting was associated with a significantly higher salvage index (the primary end point), defined as the proportion of initial perfusion defect salvaged by rescue intervention as measured at 7 to 10 days (35 versus 25 percent). In addition, there was an expected reduction in repeat revascularization.",
"   </p>",
"   <p>",
"    The REACT trial is the most relevant study of rescue PCI to current practice due to the high rate of stents (as opposed to PTCA) and of current antiplatelet therapies utilized in the trial. Failed fibrinolysis was defined as less than 50 percent ST segment elevation resolution within 90 minutes after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Patients with cardiogenic shock were excluded. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis of primary failure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H7#H7\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'ST segment elevation resolution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    REACT randomly assigned 427 patients with an ST elevation MI and failed fibrinolysis to conservative medical therapy, repeat fibrinolysis with a fibrin-specific agent, or rescue PCI (69 percent with stenting). PCI was performed within 12 hours of the onset of pain if angiography revealed less than TIMI grade 3 flow and more than 50 percent stenosis in the infarct-related artery. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Repeat fibrinolysis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'TIMI grade 2 flow'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following significantly improved outcomes were noted with rescue PCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of event-free survival (primary end point of death, reinfarction, stroke, or severe heart failure) at six months (85 versus 69 and 70 percent with repeat fibrinolysis or conservative therapy, adjusted hazard ratio 0.43 [95% CI 0.26-0.72] and 0.47 [95% CI 0.28-0.79]) and at one year (82 versus 64 and 68 percent adjusted hazard ratio 0.44 [95% CI 0.28-0.71] and 0.51 [95% CI 0.32-0.83] respectively).",
"     </li>",
"     <li>",
"      A lower rate of all-cause mortality at a median follow-up of 4.4 years (6.2 versus 12.7 and 12.8 percent with repeat fibrinolysis or conservative therapy)",
"     </li>",
"     <li>",
"      A higher rate of freedom from revascularization at one year (85 versus 67 percent with either repeat fibrinolysis or conservative therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     TIMI grade 2 flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above studies largely evaluated the efficacy of rescue PCI in patients most of whom had failed fibrinolysis (TIMI grade",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    flow), although some patients with TIMI grade 2 flow were enrolled. Thus the optimum treatment in patients with TIMI grade 2 flow is less well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/10,32,33\">",
"     10,32,33",
"    </a>",
"    ]. As noted above, patients with TIMI grade 2 flow have higher mortality rates than those with TIMI grade 3 (normal) flow: 7.0 versus 3.7 percent in a meta-analysis (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Importance of restoration of normal flow'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional evidence to support rescue PCI for patients with TIMI grade 2 flow comes from an analysis of 668 patients (105 of whom were treated with rescue PCI) with TIMI grade 2 or 3 flow at angiography in the TIMI 10B trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/10\">",
"     10",
"    </a>",
"    ]. Rescue PCI was associated with a trend toward a reduction in mortality at two years (4 versus 11 percent).",
"   </p>",
"   <p>",
"    Although the evidence to support rescue PCI for patients with TIMI grade 2 flow is less robust than that for TIMI grade",
"    <span class=\"nowrap\">",
"     0/1,",
"    </span>",
"    we suggest this approach. This is based upon the inclusion of such patients in REACT and the increasing data suggesting benefit from routine angiography and PCI after fibrinolysis when appropriately timed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rescue PCI'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Technical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two technical issues with rescue PCI are the relative value of direct stenting without balloon predilation and the optimal residual stenosis. The potential benefit of direct stenting in STEMI patients with suboptimal reperfusion after primary PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756041#H24756041\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Direct stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An optimal residual stenosis (RS) of less than 20 percent has been recommended in all patients after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/34\">",
"     34",
"    </a>",
"    ]. One review of 748 patients in the TIMI trials who underwent rescue or adjunctive PCI after fibrinolytic therapy found that patients with less than 0 percent RS were less likely to achieve normal myocardial perfusion than those with 0 to 20 percent RS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/35\">",
"     35",
"    </a>",
"    ]. This was manifested by an almost significant trend toward a lower rate of TIMI flow grade 3 (normal flow) and a significantly higher rate of abnormal TIMI myocardial perfusion grades",
"    <span class=\"nowrap\">",
"     0/1/2",
"    </span>",
"    (69 versus 53 percent). The factors responsible for these unexpected findings in this study are not well understood.",
"   </p>",
"   <p>",
"    We recommend that an attempt be made to fully expand and appose all stents at the time of PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;If rescue PCI (usually with stenting) is performed, it appears to be important that it be undertaken quickly. In general, we begin to mobilize patients with apparent failure to the cardiac catheterization laboratory at approximately 45 to 60 minutes following fibrinolysis. PCI or, if appropriate, bypass surgery is performed in patients with less than TIMI grade 3 flow. Revascularization may be deferred in patients with TIMI 3 flow who are hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/14\">",
"     14",
"    </a>",
"    ]. However, observational data suggest that even patients with TIMI 3 flow have reduced mortality if PCI is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Repeat fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat fibrinolysis for failed primary fibrinolysis is less well studied. The REACT trial discussed above included 142 such patients. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rescue PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A 2007 meta-analysis included three trials that randomly assigned 410 patients to repeat fibrinolysis (all with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) or conservative therapy with follow-up between in-hospital discharge and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/31\">",
"     31",
"    </a>",
"    ]. There was no significant difference in all-cause mortality, reinfarction, or stroke between the two groups and both treatments were inferior to rescue PCI. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rescue PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THREATENED REOCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Threatened reocclusion is best treated with immediate PCI. Patients should be referred to a facility with PCI capability soon after fibrinolysis in most cases so that threatened reocclusion can be managed expeditiously. This strategy will avoid the need to consider repeat lysis except in rare cases.",
"   </p>",
"   <p>",
"    As mentioned above, early recurrent ischemia (threatened reocclusion) after apparently successful fibrinolysis has been observed in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], thrombotic coronary reocclusion in 5 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/6,21,22\">",
"     6,21,22",
"    </a>",
"    ], and reinfarction in 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis of threatened reocclusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reocclusion of an infarct-related artery after reperfusion therapy is associated with a significant increase in mortality and worse infarct zone function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In two reviews of almost 76,000 patients from GUSTO-I, GUSTO-III, and the TIMI and InTIME-II trials, reinfarction occurred in 4.3 percent of patients at a median of two to four days after fibrinolytic therapy and was independent of the fibrinolytic agent used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Patients with reinfarction had a higher overall mortality rate at 30 days (11.3 to 16.4 versus 3.5 to 6.2 percent without reinfarction). The data were conflicting as to whether 30 day survivors of reinfarction do [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/23\">",
"     23",
"    </a>",
"    ] or do not [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/24\">",
"     24",
"    </a>",
"    ] have a modest increase in risk from 30 days to one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     PCI for threatened reocclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI is the treatment of choice for patients with recurrent MI. The magnitude of the benefit was illustrated in a retrospective review of 20,100 patients from the TIMI and InTIME-II trials of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/24\">",
"     24",
"    </a>",
"    ]. Among the 4.2 percent with a recurrent MI, the in-hospital mortality was 23.6 percent in those who were treated medically and did not undergo revascularization compared to 5.2 percent with PCI; an equivalent benefit was seen with the smaller number of patients who underwent coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p>",
"    A similar dramatic reduction in mortality with revascularization was noted in a review from the GUSTO-I and ASSENT-2 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the 4 percent of patients with reinfarction, 30-day mortality was significantly lower in patients treated with revascularization compared to medical therapy (11 versus 28 percent). The revascularization procedure was PCI or surgery (performed in 35 percent in United States centers and 15 percent in centers in other countries) or repeat thrombolysis (performed in 28 percent in United States centers and 47 percent in centers in other countries). Thirty-day mortality (11 percent) was not affected by the type of revascularization.",
"   </p>",
"   <p>",
"    PCI or surgery is also warranted in patients with an STEMI who, after fibrinolytic therapy, develop spontaneous symptomatic angina or inducible post-MI ischemia on a predischarge exercise test. Benefit from invasive therapy was demonstrated in the DANAMI trial in which 1008 such patients were randomly assigned to conservative therapy or to revascularization with PCI or CABG two to ten weeks after the MI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/36\">",
"     36",
"    </a>",
"    ]. Revascularization was associated with a lower rate of reinfarction and admission for unstable angina; mortality after a median follow-up of 2.4 years was equivalent in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Repeat fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of retreatment with a fibrinolytic agent has been evaluated primarily in patients with threatened reocclusion. Most retreatment studies have involved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and, to a lesser degree, other nonantigenic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    ; streptokinase should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because of antigenicity and relative resistance.",
"   </p>",
"   <p>",
"    Patients should be referred to a facility with PCI capability soon after fibrinolysis in most cases so that failed lysis or threatened reocclusion can be managed expeditiously. This strategy will avoid the need to consider repeat lysis except in rare cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Alteplase",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different concerns about the reuse of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) or other tissue plasminogen activators that are not known to be antigenic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two major problems with repeat fibrinolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excess bleeding risk, particularly with early reuse",
"     </li>",
"     <li>",
"      Decreased efficacy, in view of initial treatment failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of reports have demonstrated the feasibility and efficacy of repeat fibrinolytic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. As an example, a retrospective study assessed the outcome of repeat infusions of alteplase in 52 patients with an acute MI who developed early recurrent myocardial ischemia with threatened reinfarction after initial therapy with either alteplase (46 patients) or streptokinase (six patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/39\">",
"     39",
"    </a>",
"    ]. Retreatment was given within one hour of the first infusion in 67 percent and within 72 hours in 92 percent. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete resolution of acute ischemia within one hour of the second infusion was achieved in 85 percent; one-half of these patients had a sustained response and avoided further coronary intervention.",
"     </li>",
"     <li>",
"      Bleeding complications occurred in 19 percent, but only 4 percent required transfusion.",
"     </li>",
"     <li>",
"      Fibrinogen levels fell by 25 percent and plasminogen levels by 63 percent; these changes were only slightly greater than those in patients who had received only one",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      infusion and were not additive to those observed after the first infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study evaluated the effects of retreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    given for early signs of reocclusion after fibrinolysis, as manifested by recurrent chest pain lasting for more than 30 minutes with reelevation of the ST segment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/40\">",
"     40",
"    </a>",
"    ]. This complication occurred in 26 of 652 patients (4 percent) treated with alteplase, usually within 24 hours of the first infusion, particularly if intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was not used. The second dose of alteplase was 50 mg when threatened reocclusion occurred within 24 hours of initial therapy and 100 mg after 24 hours. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients had a good clinical response to retreatment; the new ST changes disappeared and pain resolved within 100 minutes (median 50 minutes).",
"     </li>",
"     <li>",
"      Angiographic findings, determined at one hour, were less favorable. Coronary artery patency was observed in 73 percent of patients who had received intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and only 40 percent of those not receiving heparin.",
"     </li>",
"     <li>",
"      Bleeding rates were similar to those after a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials have not been performed to assess the comparative efficacy of repeat fibrinolysis and PCI in patients with recurrent ischemia or threatened reinfarction. This issue was assessed in a retrospective review of the 4 percent of patients (n = 2301) who developed early reinfarction after initial fibrinolysis in the GUSTO-I (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) and ASSENT 2 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    ) trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/25\">",
"     25",
"    </a>",
"    ]. Repeat fibrinolysis (performed in 28 percent in United States centers and 47 percent in centers in other countries) and revascularization with PCI or surgery (performed in 35 percent in United States centers and 15 percent in centers in other countries) were equally effective and were associated with a significantly lower 30-day mortality than conservative therapy (11 and 11 versus 28 percent) without any increase in the rate of stroke.",
"   </p>",
"   <p>",
"    Thus, repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    infusions are feasible, can stabilize a substantial number of patients with threatened early infarction, and, even when relief of ischemia is temporary, can reduce myocardial damage in those proceeding to mechanical or surgical revascularization. However, there is limited information regarding the safety of PCI or surgery in the early hours after a second course of therapy with alteplase or other fibrinolytic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Streptokinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptokinase and its congeners are derived from bacterial proteins and are intensely antigenic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .) Neutralizing antibodies that may be present because of prior streptococcal infection or prior streptokinase therapy may limit the effectiveness of streptokinase.",
"   </p>",
"   <p>",
"    An initial series of 333 patients evaluated the influence of pretreatment antistreptokinase antibodies on the efficacy of intravenous streptokinase and anistreplase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/41\">",
"     41",
"    </a>",
"    ]. Variations in pretreatment circulating levels of antibody did not influence angiographically defined early (two hour) coronary patency rates for either agent. Similarly, the lytic response, as measured by changes in plasma plasminogen and fibrinogen levels after dosing, was not correlated with baseline antibody levels nor was pretreatment antibody a risk factor for a poor clinical outcome.",
"   </p>",
"   <p>",
"    There were two limitations to this study: there were few patients with very high antistreptokinase antibody titers; and reexposure, which induces high levels of antistreptokinase antibodies, was not evaluated. Furthermore, another report suggested that pretreatment antistreptokinase titers can have a small negative impact on outcomes in previously unexposed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of streptokinase resistance in both initial therapy and after retreatment with streptokinase was evaluated in a review of 30 healthy volunteers and 40 patients with an acute MI, 20 of whom were retreated with streptokinase after one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/43\">",
"     43",
"    </a>",
"    ]. As in the previous study, titers of antistreptokinase antibodies and the prevalence of streptokinase resistance (by in vitro assay) were low in patients presenting with their first MI. However, resistance developed early after treatment, detectable in one patient after three days and in all patients by day 10. At day 10, there was a marked elevation in antistreptokinase antibody titers (773 versus a baseline value of 18",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    by ELISA) and a marked reduction in responsiveness to streptokinase (17 percent of control). Among the 20 patients with previous streptokinase therapy, resistance was still present in 15 at up to 24 months. Antistreptokinase antibodies may remain elevated for as long as 7.5 years after streptokinase therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that the response to repeat therapy may remain suboptimal and that an allergic reaction can occur many years after the first exposure. Thus, retreatment with streptokinase or anistreplase should be",
"    <strong>",
"     avoided",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other antithrombotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few adjunctive agents have been proposed for threatened reocclusion or reinfarction, but clinical experience is limited. These include optimal antithrombin therapy (eg, optimal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing), and antiplatelet therapy (eg, with a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonist).",
"   </p>",
"   <p>",
"    As noted above, the response to repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    is reduced in patients who are not treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/40\">",
"     40",
"    </a>",
"    ]. Suboptimal or inadequate anticoagulation with heparin is also associated with lower coronary patency rates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/45\">",
"     45",
"    </a>",
"    ], while overly aggressive heparin is associated with an increased risk of hemorrhagic events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors as primary therapy for an acute MI was illustrated in the SPEED and TIMI 14 trials in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    alone restored TIMI grade 3 flow in 27 to 32 percent of patients at 60 to 90 minutes (compared to 61 to 76 percent with abciximab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    or reduced dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These drugs have not been formally tested for threatened reocclusion after fibrinolysis. One report addressed a possibly related issue: the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    to stabilize and reverse threatened reocclusion after coronary angioplasty (\"rescue ReoPro\") [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/50\">",
"     50",
"    </a>",
"    ]. In this observational study of 29 patients in whom attempted angioplasty caused new or further progression of thrombus, abciximab reduced the thrombus score and improved the TIMI flow grade from 2.5 to 2.9. The procedural success rate was 97 percent and the clinical success rate was 93 percent. Bleeding occurred in two patients and death in one. Further emergent intervention (angioplasty, stenting, or bypass surgery) was avoided in all but one patient (3 percent).",
"   </p>",
"   <p>",
"    Other trials have evaluated the efficacy of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor with lower doses of fibrinolytic therapy to improve early reperfusion success and reduce subsequent reocclusion and reinfarction. Thus far, no mortality benefit has been demonstrated and there is an increased risk of bleeding, particularly in older adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link&amp;anchor=H23#H23\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\", section on 'GP IIb/IIIa inhibitors and reduced dose fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following approach for patients experiencing postfibrinolysis-threatened reocclusion as manifested by recurrent ischemia or reinfarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom threatened reocclusion is associated with hemodynamic compromise should be treated with intraaortic balloon counterpulsation, immediate cardiac catheterization, and PCI or surgical revascularization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with objective evidence for recurrent ischemia or infarction should be rapidly treated with angiography followed by PCI or CABG or with repeat fibrinolysis using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      or other nonantigenic fibrinolytic agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       reteplase",
"      </a>",
"      ) along with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and optimal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Objective evidence includes persistent or recurrent chest pain associated with new or worsening ST segment elevation, the development of new ischemic ECG changes after initial resolution, or a second elevation in cardiac markers.",
"     </li>",
"     <li>",
"      We prefer angiography and revascularization in these patients, assuming, as with primary PCI, that catheterization can be performed within two hours. If catheterization will be delayed, repeat fibrinolysis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      or another nonantigenic fibrinolytic agent may be preferred. Patients receiving repeat fibrinolytic therapy should be observed for stability as other medical therapies are continued or augmented. If symptoms recur, angiography and coronary intervention, as appropriate, should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CABG AFTER FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG is employed infrequently for revascularization after fibrinolysis. In an analysis of 20,092 patients from the TIMI and InTIME-II trials, CABG was performed in 1048 (5.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/24\">",
"     24",
"    </a>",
"    ]. PCI is preferred in this setting because of increased risks of perioperative mortality and major hemorrhage with CABG, especially if the interval between administration of the fibrinolytic agent and surgery is short. In an analysis from the TIMI II study, 390 patients underwent CABG after fibrinolytic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients undergoing surgery within 24 hours of study, compared to those undergoing later surgery, had higher rates of perioperative mortality (17 versus 4 percent) and major hemorrhage (74 versus 51 percent).",
"   </p>",
"   <p>",
"    The risk of bleeding for patients undergoing CABG after fibrinolysis may vary with the specific fibrinolytic agent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     Tenecteplase",
"    </a>",
"    is associated with significantly less fibrinogen depletion than either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/52\">",
"     52",
"    </a>",
"    ]. As a result, patients treated with tenecteplase may be able to undergo CABG within 24 hours of fibrinolysis more safely than patients treated with the other agents, although this has not been specifically demonstrated in clinical studies.",
"   </p>",
"   <p>",
"    While early morbidity and mortality are of concern in this setting, long term outcome is much better and suggests that surgery may be appropriate for carefully selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/24,51\">",
"     24,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations from the European Society of Cardiology (ESC) and the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACCF/AHA)",
"    </span>",
"    on the management of failed fibrinolysis or threatened reocclusion have been published in their respective STEMI 2012 and 2013 guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/27/8634/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Both guidelines make strong recommendations to perform coronary angiography with the intent to perform PCI in patients treated with fibrinolysis who have cardiogenic shock or acute severe heart failure (after presentation), intermediate- or high-risk findings on predischarge noninvasive ischemia testing, or those with ischemia that is spontaneous or provoked by minimal exertion. PCI for evidence of failed reperfusion or reocclusion was graded as a strong recommendation by the ESC and as a weak recommendation by the",
"    <span class=\"nowrap\">",
"     ACCF/AHA.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among",
"    patients treated with fibrinolytic drugs for STEMI, there are two types of failed therapy: primary failure and threatened reocclusion. Immediate percutaneous coronary intervention (PCI) is the treatment of choice for both forms. It is called rescue or salvage PCI when performed after primary failure. For this reason patients should be referred to a facility with PCI capability soon after fibrinolysis in most cases so that failed fibrinolysis or threatened reocclusion can be managed expeditiously. This strategy will avoid the need to consider repeat fibrinolysis except in rare cases.",
"   </p>",
"   <p>",
"    Primary failure of fibrinolysis occurs when there is evidence of continuing of worsening myocardial ischemia and the threatened reocclusion when there is evidence of early recurrent ischemia after apparently successful fibrinolysis. The former is often manifested clinically by persistent or worsening chest pain (particularly if associated with other symptoms such as dyspnea and diaphoresis), persistent or worsening ST segment elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic instability or heart failure. However, these clinical factors are not sufficiently predictive in all patients. As a result, in the absence of clear indications of reperfusion, the clinician must maintain a high index of suspicion for primary failure. Threatened reocclusion is characterized by the development of early recurrent ischemia after apparently successful fibrinolysis.",
"   </p>",
"   <p>",
"    For patients with evidence of primary failure of fibrinolysis, we recommend rescue PCI as opposed to either repeat fibrinolysis or conservative care (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). If rescue PCI cannot be performed within 12 hours, we suggest conservative care as opposed to repeat fibrinolysis (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Rescue PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with evidence of threatened reocclusion after fibrinolysis, we suggest PCI as opposed to either repeat fibrinolysis or conservative care (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). If PCI cannot be performed within two hours, we suggest repeat fibrinolysis with a nonantigenic agent as opposed to conservative care (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Threatened reocclusion'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/1\">",
"      Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004; 44:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/2\">",
"      Sch&ouml;mig A, Ndrepepa G, Mehilli J, et al. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol 2004; 44:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/3\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/4\">",
"      Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/5\">",
"      Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/6\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/7\">",
"      Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/8\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/9\">",
"      Holmes DR Jr, Gersh BJ, Ellis SG. Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? Am Heart J 2006; 151:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/10\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105:1909.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/13\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/14\">",
"      Goldman LE, Eisenberg MJ. Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000; 132:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/15\">",
"      de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol 2000; 85:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/16\">",
"      de Lemos JA, Morrow DA, Gibson CM, et al. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol 2001; 88:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/17\">",
"      Califf RM, O'Neil W, Stack RS, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988; 108:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/18\">",
"      de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/19\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/20\">",
"      Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/21\">",
"      Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/22\">",
"      Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/23\">",
"      Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/24\">",
"      Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/25\">",
"      Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation 2001; 103:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/26\">",
"      D&ouml;nges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/27\">",
"      Edmond JJ, French JK, Stewart RA, et al. Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. Am J Cardiol 2006; 97:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/28\">",
"      Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994; 90:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/29\">",
"      Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/30\">",
"      Carver A, Rafelt S, Gershlick AH, et al. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol 2009; 54:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/31\">",
"      Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/32\">",
"      Gibson, M, Schweiger, M, Sequeira, RF, et al for the TIMI 10B Study Group. Outcomes of adjunctive PTCA/stenting for TIMI grade 2 flow following thrombolysis (abstract). J Am Coll Cardiol 1998; 31:231A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/33\">",
"      Ellis SG, Lincoff AM, George BS, et al. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Coron Artery Dis 1994; 5:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/34\">",
"      Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/35\">",
"      Gibson CM, Kirtane AJ, Boundy K, et al. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol 2005; 45:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/36\">",
"      Madsen JK, Grande P, Saunam&auml;ki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/37\">",
"      White HD, Cross DB, Williams BF, Norris RM. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990; 64:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/38\">",
"      White H. Thrombolytic treatment for recurrent myocardial infarction. BMJ 1991; 302:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/39\">",
"      Barbash GI, Hod H, Roth A, et al. Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol 1990; 16:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/40\">",
"      Simoons ML, Arnout J, van den Brand M, et al. Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. Am J Cardiol 1993; 71:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/41\">",
"      Fears R, Hearn J, Standring R, et al. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992; 124:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/42\">",
"      Gemmill JD, Hogg KJ, Dunn FG, et al. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994; 72:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/43\">",
"      Buchalter MB, Suntharalingam G, Jennings I, et al. Streptokinase resistance: when might streptokinase administration be ineffective? Br Heart J 1992; 68:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/44\">",
"      Squire IB, Lawley W, Fletcher S, et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/45\">",
"      Arnout J, Simoons M, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992; 20:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/46\">",
"      Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994; 90:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/47\">",
"      Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/48\">",
"      Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000; 101:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/49\">",
"      Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/50\">",
"      Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. \"Rescue\" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/51\">",
"      Gersh BJ, Chesebro JH, Braunwald E, et al. Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). J Am Coll Cardiol 1995; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/52\">",
"      Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001; 103:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/53\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/54\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/27/8634/abstract/55\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 91 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8634=[""].join("\n");
var outline_f8_27_8634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Importance of restoration of normal flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis of primary failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis of threatened reocclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reinfarction in a new territory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIMARY FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rescue PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - TIMI grade 2 flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Technical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Repeat fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THREATENED REOCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PCI for threatened reocclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Repeat fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Alteplase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Streptokinase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other antithrombotic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CABG AFTER FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/91\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/91|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 1\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 2\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20759?source=related_link\">",
"      Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_27_8635="Knee pain intraartic causes";
var content_f8_27_8635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common intraarticular knee problems in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Inflammatory&nbsp;arthritis (septic or non-infectious)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gout or pseudogout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meniscal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior cruciate ligament injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior cruciate ligament injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee dislocation (Tibiofemoral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute fracture of tibial plateau or femoral condyle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress fracture of tibial plateau or femoral condyle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteonecrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteochondral lesions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8635=[""].join("\n");
var outline_f8_27_8635=null;
var title_f8_27_8636="Components of early ambulatory palliative care consultation";
var content_f8_27_8636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of early ambulatory palliative care consultation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Illness understanding/education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inquire about illness and prognostic understanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer clarification of treatment goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptom management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Inquire about uncontrolled symptoms with a focus on:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary symptoms (cough, dyspnea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatigue and sleep disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mood (depression and anxiety)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastrointestinal (anorexia and weight loss, nausea and vomiting, constipation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decision making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inquire about mode of decision making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assist with treatment decision-making, if necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Coping with life-threatening illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family/family caregivers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Referrals/prescriptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify care plan for future appointments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indicate referrals to other care providers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Note new medications prescribed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Medicine 2011; 14:459. Copyright &copy; 2011 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8636=[""].join("\n");
var outline_f8_27_8636=null;
var title_f8_27_8637="WHO class gastric ca";
var content_f8_27_8637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization histological classification of gastric tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        SNOP code",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Epithelial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Intraepithelial neoplasia - Adenoma",
"       </td>",
"       <td>",
"        8140/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adenocarcinoma",
"       </td>",
"       <td>",
"        8140/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Intestinal type",
"       </td>",
"       <td>",
"        8144/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diffuse type",
"       </td>",
"       <td>",
"        8145/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Papillary adenocarcinoma",
"       </td>",
"       <td>",
"        8260/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Tubular adenocarcinoma",
"       </td>",
"       <td>",
"        8211/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mucinous adenocarcinoma",
"       </td>",
"       <td>",
"        8480/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Signet-ring cell carcinoma",
"       </td>",
"       <td>",
"        8490/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adenosquamous carcinoma",
"       </td>",
"       <td>",
"        8560/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Squamous cell carcinoma",
"       </td>",
"       <td>",
"        8070/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Small cell carcinoma",
"       </td>",
"       <td>",
"        8041/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Undifferentiated carcinoma",
"       </td>",
"       <td>",
"        8020/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Carcinoid (well differentiated endocrine neoplasm)",
"       </td>",
"       <td>",
"        8240/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Non-epithelial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Leiomyoma",
"       </td>",
"       <td>",
"        8890/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Schwannoma",
"       </td>",
"       <td>",
"        9560/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Granular cell tumour",
"       </td>",
"       <td>",
"        9580/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Glomus tumour",
"       </td>",
"       <td>",
"        8711/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Leiomyosarcoma",
"       </td>",
"       <td>",
"        8890/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        GI stromal tumour",
"       </td>",
"       <td>",
"        8936/1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Benign",
"       </td>",
"       <td>",
"        8936/0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Uncertain malignant potential",
"       </td>",
"       <td>",
"        8936/1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Malignant",
"       </td>",
"       <td>",
"        8936/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Kaposi sarcoma",
"       </td>",
"       <td>",
"        9140/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Malignant lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Marginal zone B-cell lymphoma of MALT-type",
"       </td>",
"       <td>",
"        9699/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mantle cell lymphoma",
"       </td>",
"       <td>",
"        9673/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diffuse large B-cell lymphoma",
"       </td>",
"       <td>",
"        9680/3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SNOP: systematized nomenclature of pathology.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8637=[""].join("\n");
var outline_f8_27_8637=null;
var title_f8_27_8638="Saddle nose in RPC";
var content_f8_27_8638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saddle nose deformity in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 185px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Saddle nose deformity (arrow) due to cartilage damage in a patient with relapsing polychondritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clement J Michet, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8638=[""].join("\n");
var outline_f8_27_8638=null;
var title_f8_27_8639="Digital gangrene Raynauds I";
var content_f8_27_8639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital gangrene in Raynaud's",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with severe Raynaud's phenomenon and systemic lupus erythematosus who developed digital gangrene in the winter. She was treated conservatively, and the gangrenous digits self-amputated six months later. In patients with lupus, similar lesions can be seen with antiphospholipid antibodies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_27_8639=[""].join("\n");
var outline_f8_27_8639=null;
